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 1
1 Introduction 
 
1.1 Endometriosis 
Endometriosis is characterized by the presence of endometrial tissue outside the 
uterus most commonly in the ovary and the peritoneum but may also occur in 
pericardium, intestinal tract, lung, pleura or brain (Giudice and Kao, 2004). The 
prevalence is approximately 10% in the general female population in their 
reproductive age with 35-50% of the patients experiencing pain and infertility 
(Houston, 1984; Cramer, 1987; Rothman and Greenland, 1998; Rogers et al., 2009). 
Endometriosis is generally associated with inflammation, but, severe cases may 
result in extensive pelvic adhesions and distortion of pelvic anatomy, which could 
result in infertility (Giudice and Kao, 2004). 
  
1.1.1 Pathogenesis, Diagnosis, Classification and Therapy of Endometriosis 
The pathogenesis of endometriosis is still poorly understood and remains 
controversial. However, several theories including dissemination by retrograde 
menstruation, induction, coelomic metaplasia, altered cellular immunity, lymphatic  
and vascular metastasis, genetic causes and environmental causes have been 
presented to understand the pathogenesis and etiology of endometriosis (Giudice 
and Kao, 2004; Witz, 2005). 
The most widely accepted hypothesis of the pathogenesis of endometriosis is 
dissemination and implantation after retrograde menstruation first proposed by 
Sampson (1922; 1927). According to Sampson, some of the endometrial tissue 
fragments passes through the fallopian tubes during menstruation, then attach and 
proliferate in the peritoneal cavity (Sampson, 1927). Recent data by Matsuzaki and 
Darcha (2012) and Konrad et al. (2013, submitted) provide evidence that the 
hypothesis by Sampson is probably correct.  
However, Sampson's theory fails to explain why only a small percentage of women 
experiencing retrograde menstruation develop endometriosis (Koninckx and Martin, 
1992). Thus, other factors like the immune system might be involved in the 
implantation of displaced endometrial cells which develop into endometriotic lesions 
(Donald and Dmowski, 1998; Kyama et al., 2003). In women with endometriosis, the 
immune system seems to be impaired, hence permitting endometrial cells to escape 
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immune surveillance and to grow in ectopic locations (Donald and Dmowski, 1998; 
Herington et al., 2011).  
Diagnosis of endometriosis is by laparoscopy which is generally considered as the 
“gold standard”, followed by histological confirmation of viable ectopic endometrial 
glands and stroma (Brosens, 1997; Kennedy et al., 2005). Sometimes, a non-
invasive examination by auxiliary diagnostic methods such as pelvic ultrasound is 
used before performing surgery (Brosens, 1997; Champaneria et al., 2010). 
Peritoneal fluid, serum and tissue markers such as CD10 and CA125 have also been 
tested in some clinics but none are used routinely (Mihalyi et al., 2010).  
The revised American Society for Reproductive Medicine (rASRM) score is currently 
the best known classification of endometriosis. According to rASRM, the staging is 
based on the location, amount, depth and size of endometrial implants. Four stages 
of endometriosis have been characterized  
• Stage 1 (Minimal) 
- Findings restricted to superficial lesions only and possibly a few filmy  
          adhesions 
• Stage 2 (Mild) 
- Presence of deep lesions in the rectouterine pouch in addition to 
observations in stage1 
• Stage 3 (Moderate) 
           - Presence of endometriomas on the ovary and more adhesions in addition to   
            observations in stage 2 
• Stage 4 (Severe) 
          - Presence of large endometriomas and extensive adhesions in addition to  
            observations in stage 3 
 
Treatment of endometriosis can be medical, surgical or a combination of both. 
Treatment options depend on the severity of the symptoms, pregnancy, age and 
therapeutic goals. Endometriosis is often treated surgically, but symptoms recur in 
75% of cases within 2 years (Candiani et al., 1991). Medical treatment of 
endometriosis involves contraceptive steroids, progestagens, agonists of 
gonadotropin-releasing hormone (GnRH) analogues and non-steroidal anti-
inflammatory agents (Lessey, 2000; Kennedy et al., 2005; Valle and Sciarra, 2008; 
Kappou et al., 2010). However, because of undesirable side-effects caused by most 
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of these drugs, they are useful only for a limited time period making it necessary to 
change or use additional medication (Kuohung et al., 2002; Kennedy et al., 2005). 
 
1.1.2  In vivo and in vitro Models of Endometriosis 
a) In vivo models 
The most widely accepted hypothesis for the development of endometriosis is 
Sampson’s theory of retrograde menstruation which implies the implantation of 
retrograde endometrial tissues in tissues outside the uterus. Thus, menstrual 
shedding is a requirement for spontaneous development of endometriosis which has 
been found to occur only in human, primates and some rats (Grümmer, 2006). 
But owing to the species specificity, it is hard to compare human and primates.  For 
example, spontaneous and induced endometriosis has been found in baboons to be 
as low as 4.8% and 27.6%, respectively, raising some doubts on the validity of the 
baboon model for endometriosis (Dehoux et al., 2011). Also, the very high costs of 
animal handling limit the use of baboons as an experimental model. 
Recently, rodent models like severe combined immune deficiency (SCID) mice have 
been used also to study endometriosis. In these models, human endometrial and 
endometriotic tissue or cells were successfully engrafted into the peritoneal cavity of 
immunodeficient mice (Liu et al., 2010; Becker et al., 2011). The grafted tissues or 
cells were able to implant and develop into endometriotic lesions. The advantages of 
such models are: (1) animals are easily available, (2) low costs and (3) the peritoneal 
environment of the hosts can be altered to suit the study objectives. Mice 
xenotransplanted with human eutopic endometrial tissue developed endometriosis-
like lesions in 63% and 68% in ovariectomized estrogen-supplemented TGF-β1-null 
mutant mice and wild-type control, respectively. With the aid of this model it was 
demonstrated that host derived TGF-β1 deficiency suppressed endometriotic lesion 
development (Hull et al., 2012). 
The in vivo models of endometriosis have many advantages, but the limitations of 
such models is that they can hardly be used to study individual components and 
some biological functions like the involvement of intracellular proteins and pathways, 
These aspects of endometriosis can be addressed appropriately only by use of in 
vitro models. 
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b) In vitro models 
In vitro models of endometriosis are build by obtaining endometrial and endometriotic 
tissues from patients after surgical treatment. Primary epithelial or stromal cells are 
isolated, cultured and then used for assays. Epithelial cells derived from 
endometriotic lesions were found to be as invasive as metastatic cancer cells using 
the matrigel invasion assay (Zeitvogel et al., 2001). Another model using both 
invasion and angiogenesis within a 3D fibrin matrix demonstrated the ability of 
ectopic endometrial fragments to proliferate and invade. The fragments generated in 
vitro appeared histologically similar to endometriotic implants in vivo (Fasciani et al., 
2003). Therefore, in both models, there is a strong evidence of the possibility to study 
endometriosis in vitro. The limitations of using primary cells are that the cells are 
often heterogeneous and epithelial cells die at low passages (Starzinski-Powitz et al., 
1998).  
This problem has been sorted out by establishment of immortalized endometrial and 
endometriotic cells (Starzinski-Powitz et al. 1998; Boccellino et al. 2012).  Konrad et 
al. (2010) and Sui. (2012) showed that the above established immortalized 
endometrial and endometriotic cell lines were able to secrete or to be stimulated by 
TGF-βs. Thus, the immortalized cell lines are a suitable model for studying 
endometriosis. 
 
1.2 The Transforming Growth Factor Βetas and TGF-β Receptors 
TGF-βs are a member of a large superfamily including activins, inhibins, nodals, 
bone morphogenetic proteins (BMP), lefty A and B, growth and differentiation factors 
(GDFs) and anti-Mullerian hormones (Chang et al., 2002; Peng, 2003). TGF-βs 
comprise three isoforms namely TGF-β1, TGF-β2 and TGF-β3. Biologically, TGF-βs 
regulate cell motility, proliferation, apoptosis, gene expression and differentiation. In 
addition, TGF-βs tightly regulate production of the extracellular matrix (ECM) and are 
involved in wound healing and immunosupression (Roberts and Sporn, 1993; 
Roberts, 1998; Kaminska et al., 2005; Taylor, 2009). They are also involved in 
tumorigenesis and inflammation (Padua and Massagué, 2009; Santibañez et al., 
2011).  
Production and activation of the TGF-βs is triggered by cleavage of the inactive 
dimeric TGF-β precursor called latency associated peptide (LAP). LAP is bound by 
disulphide bonds to the latent-TGF-β binding protein (LTBP) resulting in the large 
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latent complex (LLC). The LLC is targeted either to the cell surface for activation or to 
the extracellular matrix for storage (Munger  et al., 1997; Rifkin, 2005).  
Gene knockout techniques have revealed the physiological roles of each of the TGF-
β isoforms. TGF-β1 knockout mice die at gestation due to defective vasculature 
(Shull et al., 1992; Chen et al., 1996). TGF-β2 knockout mice exhibit perinatal 
mortality and a wide range of developmental defects (Sanford et al., 1997; Shi et al., 
1999). TGF-β3 knockout mice die within 24 hours after birth due to abnormal lung 
development and feeding problems associated with a defective cleft palate 
(Kaartinen et al., 1995; Proetzel et al., 1995). 
The TGF-β family receptors are divided into three groups, namely type I, type II and 
type III receptors. The three receptor types have distinct properties (Heldin et al., 
1997; Chang et al., 2002). TGF-β receptor type I (TβRI) and type II (TβRII) are 
transmembrane serine/threonine kinases. The type III receptors, betaglycan (TβRIII) 
and endoglin are accessory receptors and have high affinity to all three TGF-β 
isoforms (Wrana et al., 1994; Gordon et al., 2008).  
The general mechanism of TGF-β signaling starts by TGF-β binding either to TβRIII, 
which presents it to TβRII, or binding to TβRII directly, which then binds to and 
transphosphorylates TβRI. Then the activated TβRI phosphorylates Smad2 or 
Smad3, which bind to Smad4 in the cytoplasm or the nucleus forming a Smad 
complex. The Smad complex interacts with transcription factors in the nucleus to 
regulate TGF-β responsive genes (Chen et al., 2003; Guglielmo et al., 2003; Biondi 
et al., 2007; Wrighton et al., 2009).  
 
1.2.1 The Smad-dependent and Smad-independent Pathways in TGF-β 
Signaling 
a) Smad-dependent Pathways 
Smads are intracellular proteins that transduce signals from the TGF-β receptors to 
the nucleus where they activate downstream gene transcription (Miyazono al., 2000). 
There are three classes of Smads, namely the receptor-regulated Smads (R-Smads) 
including Smad1, 2, 3, 5 and 8/9 (Wu et al., 2001).  The common-mediator Smad (co-
Smad) with only Smad4, which interacts with R-Smads to participate in signaling (Shi 
et al.,1997). The inhibitory Smads (I-Smads), Smad6 and Smad7, block the activation 
of R-Smads and co-Smads (Itoh et al., 2001). BMP type I receptor activates Smads1, 
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5 and 8 (Moustakas et al., 2001), while TβRI or activin receptors  activate Smad2 and 
Smad3 (Chen et al., 2003).  
 
A general Smad-dependent signaling pathway activated by TGF-β is shown in  
Figure 1  (Rebecca, 2000). 
 
 
Figure 1. The TGF-β induced Smad signaling pathway (Rebecca, 2000). Binding of TGF-β results in 
the formation of the TβRI/TβRII complex and then the TβRII kinase phosphorylates and activates 
TβRI. The activated TβRI kinase phosphorylates Smad2/Smad3. The phospho-Smad2/Smad3 form 
complexes with the co-Smad (Smad4) and move into the nucleus, where they interact with other 
transcription factors to regulate transcription.  
 
b) Smad-independent Pathways 
Smad-independent pathways which reinforce the signal transduction of the TGF-βs 
were shown by Derynck and Zhang. (2003), Moustakas and Heldin. (2005) and 
Zhang (2009). The Smad-independent pathways provide alternative TGF-β signal 
transduction without the direct involvement of Smad proteins. For instance, the p38 
substrate kinase, regulates the transcriptional activity of Smad3 by enhancing its 
association with p300 (Abécassis et al., 2004) and TGF-β-activated JNK was shown 
to phosphorylate Smad3 thus inducing its nuclear translocation (Engel et al. 1999). 
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1.2.2 TGF-βs in the Normal Endometrium and Endometriosis 
a) Normal Endometrium 
The TGF-βs are stage-specifically expressed in the human endometrium during the 
menstrual cycle (Fig. 2). TGF-β1 and TGF-β3 are highly expressed in stromal and 
glandular cells (Chegini et al., 1994). TGF-β2 was found to be strongly expressed in 
stromal cells compared to glandular cells (Gold et al., 1994; Gaide Chevronnay et al., 
2008). This observation suggests the involvement of TGF-βs in the normal function of 
the human endometrium (Omwandho et al., 2010). 
 
 
Figure 2. Levels of TGF-βs during the menstrual cycle in human endometrium. Only the start and 
endpoints of the strongest expression of the TGF-βs is shown. The three TGF-βs isoforms are 
differentially and highly expressed during the menstrual cycle (Omwandho et al., 2010). 
 
b) TGF-βs in Endometriosis 
TGF-βs were found to be expressed significantly higher in the serum and peritoneal 
fluid in women with endometriosis (Pizzo et al., 2002). Also, TGF-βs levels are 
enhanced markedly concomitant with the severity of the disease with high levels 
observed in stages III and IV, suggesting a possible role in the pathogenesis of 
endometriosis (Pizzo et al., 2002). 
Endometriosis comprises six developmental stages namely cell shedding and 
refluxing, cell survival, immune suppression, cell adhesion and invasion, 
angiogenesis, and bleeding (Omwandho et al., 2010). TGF-βs have been shown to 
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be directly or indirectly involved in most of these stages (Fig. 3). 
 
 
 
 
Figure 3. The six developmental stages leading to endometriosis. The involvement of the TGF-βs 
directly or indirectly in each stage has been emphasized (Omwandho et al., 2010). 
 
Retrograde menstruation is the most widely accepted theory of pathogenesis of 
endometriosis (Sampson, 1927), thus for establishment of endometriosis to occur, 
shedding and refluxing of endometrial cells are prerequisites. Highest expression of 
the TGF-βs was detected during menstruation, suggesting a possible involvement of 
the TGF-βs in cell shedding (Gaide Chevronnay et al., 2008). Also, women with 
endometriosis were found to experience abnormal myometrial contractions with 
higher and a different frequency (Bulletti et al., 2002), which is possibly associated 
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with the dissemination of endometrial fragments. 
TGF-βs regulate a wide variety of cellular responses including proliferation, 
apoptosis, gene expression, immune responses, cell motility, tumorigenesis, immune 
responses and extracellular matrix production (ECM) (Derynck et al., 2001). 
Interestingly, TGF-β effects can be extremely variable depending on cell types and 
stimulation context. For example, TGF-βs cause growth arrest in epithelial cells, but 
induce activation of fibroblasts (Rahimi and Leof, 2007). In endometrial cells, TGF-β1 
was found to stimulate DNA synthesis of epithelial cells with lower cell number, but 
repressed it when the cell number was higher in women with and without 
endometriosis (Meresman et al., 2003). 
Escape of endometrial fragments from apoptosis and immune attack as they enter 
and transit the peritoneal cavity is also very important for their survival. TGF-β1 can 
induce expression of FasL mRNA in endometrial stromal cells (Garcia-Velasco  et al., 
1999), possibly preventing apoptosis during transit of the peritoneal cavity. In 
addition, TGF-β1 can inhibit IFN-γ and IL-10 secretion by uterine NK cells from 
human endometrium but upon blocking of TGF-β1, secretion of the two cytokines 
was increased (Eriksson et al., 2004). In general, the high levels of the TGF-βs might 
have a direct or indirect effect on the immune escape by decreasing the response of 
NK cells to ectopic endometrial fragments hence increasing their survival rate.  
TGF-βs might be regulating cell adhesion to the ECM indirectly through regulating 
the balance of matrix metalloproteinases (MMPs) and tissue inhibitor of 
metalloproteinases (TIMPs) which are involved in the normal fibrolytic processes. 
Also MMPs have been shown to convert the inactive membrane-bound FasL, to its 
active soluble form which induces apoptosis (Otsuki, 2001). Taken together, TGF-βs 
might be involved in most of the biological processes involved in the pathogenesis of 
endometriosis, although more studies are needed to clarify their exact participation. 
 
1.3 TGF-β-induced Apoptosis in Human Endometrium and Endometriosis 
1.3.1 Apoptosis 
Apoptosis (programmed cell death) enables multicellular organisms to remove 
excessive and potentially dangerous cells. Balance and coordination between 
apoptosis and cell survival is important for homeostasis and development of 
multicellular organisms (Green, 1998). A defect in the control of the balance may 
cause diseases like cancer, neurodegenerative conditions and autoimmune diseases 
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(Kroemer et al., 2007). The morphological alteration of cells undergoing apoptosis is 
caused mainly by cysteine protease proteins, called caspases, which are mainly 
activated in cells undergoing apoptosis (Green, 1998). 
The process of apoptosis is characterized by cell shrinkage, chromatin condensation, 
DNA fragmentation and formation of cytoplasmic blebs (Elmore, 2007). Two major 
apoptotic pathways exist in mammalian cells, the mitochondrial pathway (intrinsic) 
and the death-receptor pathway (extrinsic). The two pathways are initiated by 
different mechanisms but both cause activation of caspases which eventually result 
in apoptosis. 
 
1.3.2 TGF-β-induced Apoptosis 
Uterine cells have been shown to undergo apoptosis during blastocyst implantation, 
oestrous cycle and decidualization. The control of the coordinated blastocyst 
implantation processes presumably depends on secretion of various endometrial 
factors, among them TGF-βs (Pollard, 1990). 
TGF-β1 and TGF-β2 mRNAs have been detected in decidual cells after the first week 
of pregnancy (Tamada et al., 1990; Manova et al., 1992). TGF-β1 has been reported 
to increase apoptosis in primary cell cultures of uterine epithelial cells (Rotello et al., 
1989), also TGF-β1 and TGF-β2 stimulated the increase in nucleosome DNA 
fragmentation in endometrial stromal cells indicating stimulation of apoptosis (Bruce, 
1994). Furthermore, neutralization of TGF-βs secreted by endometrial stromal cells 
completely inhibited apoptosis in vitro (Bruce, 1994). All above data strongly show 
that TGF-βs are an important component in apoptosis of stromal and epithelial cells.  
 
1.3.3 TGF-β-induced Apoptosis in the Human Endometrium  
Apoptosis occurs in normal endometrial tissue throughout the cycle and is important 
in maintaining the homeostasis of cells during the menstrual cycle. Specific nuclear 
DNA fragmentation related to apoptosis was reported in the human endometrium 
(Hopwood and Levinson 1995). The B-cell lymphoma/Leukemia-2 protein (Bcl-2), an 
anti-apoptotic protein, is expressed throughout the menstrual cycle with higher levels 
in the glandular component of the human epithelium (Gombel et al., 1994, Otsuki et 
al., 1994: McLaren et al., 1997). 
The Bcl-2 immunoreactivity was maximal in the proliferative endometrium and the 
levels decreased to a minimum in the secretory endometrium (Tao et al., 1997). In 
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contrast, levels of the pro-apoptotic proteins, Bax and Fas/FasL, were increased in 
the secretory endometrium with minimal expression in the glandular epithelium 
(Watanabe et al., 1997; Meresman et al., 2000). Furthermore, in Bcl-2-deficient mice, 
many apoptotic cells and bodies were often observed in glands and myometrium 
(Daikoku et al., 1998), implying that Bcl-2 may be essential in survival of both 
endometrial glandular cells and myometrial smooth muscle cells (Meresman et al., 
2000). 
Coincidently, TGF-βs have been shown to be stage-specifically and abundantly 
expressed throughout the menstrual cycle with higher levels expressed in both 
stromal and glandular cells (Chegini et al., 1994; Gaide Chevronnay et al., 2008). 
The mRNA and protein expression of TGF-βs is high in the late secretory phase of 
the menstrual cycle (Omwandho et al., 2010). Also the levels of the pro-apoptotic 
proteins, Bax and Fas/FasL, are high in the secretory phase while the anti-apoptotic 
protein, Bcl-2 expression, is low in the secretory phase of the menstrual cycle (Tao et 
al., 1997; Watanabe et al., 1997; Garcia-Velasco et al., 1999; Meresman et al., 
2000). Other studies have shown that TGF-β1 increased the apoptotic rate of 
endometrial stromal cells in vitro (Chatzaki et al., 2003).  
We can only speculate that the stage-specific expression of TGF-βs, Bax, Fas/FasL 
(direct correlation) and Bcl-2 protein (inverse correlation) throughout the menstrual 
cycle indicates that TGF-βs might induce apoptosis of human endometrial stromal or 
epithelial cells in human endometrium during the secretory phase of the menstrual 
cycle. Further studies are needed to characterize the apoptotic effects of the TGF-βs 
and which apoptotic pathways are involved in the normal endometrium and 
endometriosis. 
 
1.3.4 TGF-β-induced Apoptosis in Endometriosis 
The role of TGF-β-induced apoptosis in endometriosis has not been well studied, 
however, the escape of endometrial fragments from apoptosis as they enter and 
transit the peritoneal cavity is very important for their survival (Garcia-Velasco et al., 
1999). In addition, women who develop endometriosis showed greatly reduced 
apoptosis in sloughed endometrial cells, implying that a high number of surviving 
cells can enter the peritoneal cavity (Gebel et al., 1998).  
Apoptosis was found to decrease as the severity of endometriosis increases 
(Dmowski et al., 2001). Also, Bcl-2 protein expression was found to be increased in 
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proliferative eutopic endometrium in women with endometriosis, suggesting a 
possible resistance to apoptosis (Meresman et al., 2000). Furthermore, FasL is highly 
expressed in endometriotic tissues which possibly contributes to their survival and 
thus to the development of endometriosis. Also higher levels of soluble FasL were 
present in serum and peritoneal fluid of women from endometriosis (Garcia-Velasco 
et al., 2002), which might contribute to increased apoptosis of Fas-expressing 
immune cells. Garcia-Velasco et al. (1999) showed that platelet-derived growth factor 
(PDGF) and TGF-βs are increased in peritoneal fluid of women with endometriosis. 
Also, PDGF and TGF-βs induced FasL expression by endometrial stromal cells 
(Garcia-Velasco et al.,1999). Increased FasL expression by the cells may protect the 
stromal cells from cytotoxic T-cells, hence ectopic endometrial cells are able to 
escape the immune system in the peritoneal cavity of women with endometriosis 
hence possibly contributing to the pathogenesis and maintenance of the disease. 
Furthermore, FasL expression by endometriotic cells was induced after adhesion of 
the cells to ECM proteins of endometriotic patients (Selam et al., 2002), this possibly 
induces apoptosis of activated T-lymphocytes thereby lowering their ability to attack 
the endometrial cells. Thus, survival of endometriotic cells is promoted during initial 
attachment at ectopic sites.  
Increased expression of FasL, Bcl-2 and TGF-βs in serum, peritoneal fluid and 
ectopic sites in women with endometriosis suggests the possible involvement of 
TGF-βs in apoptosis during entry and transit of endometrial cells in the peritoneal 
cavity, subsequent attachment of the cells at ectopic sites and eventual 
establishment and maintenance of endometriosis. 
Although, the role of TGF-β-induced apoptosis in endometriosis has not been fully 
investigated, recently, Omwandho et al. (2010) showed that the stages of 
endometriosis are similar to those of cancer. Since TGF-βs have been shown to play 
an important role in suppression of apoptosis in various tumors (Lebrun, 2012), 
together with their increased expression in serum, peritoneal fluid and at 
endometriotic sites of women suffering from endometriosis, it will be of great 
importance to find out if the TGF-βs induce apoptosis in endometriotic cells and by 
which mechanisms. 
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1.4 Crosslink of TGF-β and Bone Morphogenetic Proteins (BMPs)   
The BMPs are multifunctional proteins that regulate functions such as proliferation, 
apoptosis and differentiation of a large variety of cell types (Reddi, 1997). BMPs 
mediate their cellular functions through binding to a combination of type I and type II 
receptor serine/threonine kinases (Kawabata et al., 1998). The BMP ligands can bind 
to any of the three type II receptors (BMPRII, ActRIIa and ActRIIb) which then bind to 
one of the three type 1 receptors (ALK-2, ALK-3 and ALK-6). Upon binding, the 
constitutively active type II receptor phosphorylates type 1 receptor then 
phosphorylates the BMP-responsive Smad proteins namely Smad1, Smad5 and 
Smad 8. The activated Smads bind Smad4 either in the cytoplasm or in the nucleus 
for signaling (Yu et al., 2008). In addition, BMP signals have been found to activate 
other intracellular effectors like mitogen-activated protein kinase (MAPK) p38 via the 
Smad pathway (Nohe et al., 2004). 
Although TGF-βs transduce their signals through activation of Smad2 and Smad3 
(Chen et al., 2003), recent studies have indicated that they can also strongly but only 
transiently induce phosphorylation and activation of Smad1, Smad5 and Smad8 
(BMP-responsive Smads) in endothelial cells, epithelial cells, fibroblasts and 
epithelium derived cancer cells (Bharathy et al., 2008; Daly et al., 2008; Liu et al., 
2009). These observations have raised several questions of how the activation of 
Smads1/5/8 by TGF-βs affect BMP responses (Grönroos et al., 2012).  
Several hypothesis have been put forward to explain the possible crosstalk of      
TGF-βs/BMP pathways, for example Grönroos et al., 2012 suggested the 
involvement of ALK-5 and formation of pSmad3-pSmad1/5 complexes. Recently, 
knockdown of Smad3 phosphorylation in mice abolished the ability of TGF-β to inhibit 
BMP-induced transcription (Grönroos et al., 2012), further supporting a possible 
crosstalk between TGF-β and BMP pathways. 
Perturbations of both BMP and TGF-β signalling have been reported to cause distinct 
bone diseases (Jansens et al., 2000). In endothelial cells, ALK-1 together with ALK-5 
can activate TGF-β-responsive Smads (Smad2/3) and also phosphorylate BMP-
responsive Smads (Smad1/ 5/ 8; Miyazono and Kusanagi, 2001). Furthermore, 
Smad5-deficient mice exhibit defects in vascular tissues (Chang et al., 1999), which 
are similar to those observed in ALK-1 deficient mice. These observations suggest 
that Smad5 is a downstream target of ALK-1 (Miyazono and Kusanagi, 2001). In 
addition, molecules that repress both TGF-βs and BMPs have been found to be 
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involved in the pathogenesis of vascular diseases (Miyazono and Kusanagi, 2001), 
hence indicating a possible crosstalk of both pathways. What remains to be 
investigated is the exact location of cross-talk of the TGF-β and BMP pathways (e.g. 
at the extracellular membrane, in the cytoplasm or in the nucleus) and which 
molecules are involved (e.g. the individual BMP/TGF-β receptors or Plasminogen 
Activator Inhibitor 1 (PAI-1) secretion among other proteins. These will be helpful in 
determining the cross-talk of TGF-β and BMP pathways and understand their 
possible role in the pathophysiology of endometriosis. 
 
1.5 Plasminogen Activator Inhibitor-1 
PAI-1 is the major inhibitor of tissue-type plasminogen activator (tPA) and urokinase-
type plasminogen activator (uPA) in vitro and is pivotal in fibrinolysis (Binder et al., 
2002; Czekay and Loskutoff, 2004). The promoter region of PAI-1 contains three 
Smad binding elements (SBEs), which are the main response element of TGF-β 
signals (Binder et al., 2002).  
Endothelial and stromal cells are the main producers of PAI-1 which is then released 
into the plasma (Bastelica et al., 2002; Vaughan, 2005). Expression of PAI-1 and 
uPA was shown to be much higher in endometriotic and endometrial tissues of 
women with endometriosis compared to tissue from women without endometriosis 
(Bruce et al., 2004). PAI-1 is able to regulate levels of cell surface integrins through 
triggering their internalization by binding to the low-density lipoprotein receptor-
related protein-1 (LRP1) resulting in detachment of cells from various substrates 
(Akkawi et al., 2006;  Pedroja et al., 2009; Czekay et al., 2011). 
Recently, studies have shown that PAI-1 and TGF-βs are involved in fibrosis, wound 
healing and metastasis and are capable of inducing ECM remodeling through 
regulation of plasmin and MMP acitivity (Kortlever and Bernards, 2006). Furthermore, 
activity of TGF-βs is involved in the conversion of fibroblasts to myofibroblasts 
(Desmouliere et al., 2004), that are responsible for PAI-1 secretion at the edges of 
stromal tissue during cancer invasion (Dublin et al., 2000; Offersen et al., 2003). 
Given the fact that both TGF-β and PAI-1 are involved in fibrosis, wound healing, 
metastasis, induction of ECM remodeling and regulation of MMP activity and that 
their activities (TGF-β and PAI-1) are elevated in endometrial and ectopic tissues in 
women with endometriosis, thus we suppose that TGF-β/PAI-1 might play an 
important role in the pathogenesis of endometriosis. It will be interesting to 
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investigate whether or not, PAI-1 contributes to the pathophysiology of endometriosis 
and which pathways are involved. 
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1.6 Objectives 
Despite the fact that TGF-βs have been demonstrated to play important roles in the 
pathogenesis of endometriosis, their precise function needs to be investigated in 
more depth. TGF-βs have been shown to mediate their functions via Smad 
molecules. Of note, cross-talk with other signaling pathways has been reported, but 
the exact molecules involved have not been fully established. Thus, it will be 
interesting to examine the distinct molecules involved (Smads and receptors) and the 
cross-talk with other pathways like BMPs to better understand the pathogenesis of 
endometriosis. Furthermore, PAI-1 expression has been found to be regulated by 
TGF-β isoforms in many tissues, thus it will be of great importance to elucidate how 
TGF-βs regulate the expression of this protein and the pathways utilized for its 
regulation. 
Endometriosis has been studied by the use of immortalized endometriotic and 
endometrial cell lines (for comparison) both of which have been characterized well. 
Thus both endometrial and endometriotic cell lines together with primary endometrial 
stromal cells will enable us to establish an in vitro model which will allow a deeper 
understanding of the basic aspects and provide comparisons of endometriotic cells to 
normal endometrial cells. 
The main objective of this study was to investigate the influence of TGF-βs on 
endometrial, endometriotic cell lines and primary endometrial stromal cells in regard 
to cell numbers, regulation of some proteins essential in endometriosis and TGF-β 
receptor interactions. The study will further investigate the signaling pathways of 
TGF-βs and possible cross-talks with other pathways in endometrial and 
endometriotic cell lines and primary endometrial stromal cells in vitro. In addition, the 
different characteristics of normal endometrial cells and endometriotic cells observed 
in all the above aspects will be reported. 
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2 Materials and Methods 
 
2.1 Human Immortalized Endometrial, Endometriotic Cell Lines and Primary 
Endometrial Stromal cells 
 
2.1.1 Endometrial Epithelial and Stromal Cells 
The HES cells are a spontaneously immortalized human endometrial epithelial cell 
line (Fig. 4). The cells express E-cadherin, vimentin and cytokeratin (Desai et al., 
1994) and estrogen receptor alpha (Banu et al., 2008). 
The T-HESC cells (Fig. 4) are telomerase immortalized endometrial stromal cells 
(Krikun et al., 2004). T-HESC exhibit considerable and constitutive expression of 
progesterone receptor mRNA (Leila et al., 2011). The estrogen receptor beta and P-
450 aromatase are strongly expressed also in T-HESC (Banu et al., 2008). The cells 
undergo decidualization after treatment with estrogen plus medroxyprogesterone 17-
acetate (Krikun et al., 2004).  
 
 
 
 
 
 
 
 
Figure 4. Human endometrial epithelial (HES) and stromal (T-HESC) cells. The HES cells are 
triangular, flat and strongly aggregate indicating epithelial cell-to-cell contacts. The T-HESC cells show 
a spindle-shaped, fibroblastoid morphology and are larger in size compared to HES. They are often 
scattered when their numbers are few, however, they often aggregate in parallel clusters when 
crowded.   
 
2.1.2 Endometriotic Epithelial and Stromal Cells 
12ZVK are epithelial-like endometriotic cells and are immortalized with SV40   (Fig. 
5). They express cytokeratins, E-Cadherin and vimentin usually present in 
endometrial epithelial tissue (Zeitvogel et al., 2001). They express steroidogenic 
acute regulatory protein, the estrogen receptor α and β, progesterone receptor and 
steroidal stimulating factor-1 (Banu et al., 2008). 
HES T-HESC 
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The 22B cells are stromal-like endometriotic cells and have been immortalized with 
SV40 (Fig. 5). They express cytochrome P-450 mRNA abundantly and estrogen 
receptor β. 22B are E-Cadherin-negative but they are vimentin-positive (Zeitvogel et 
al., 2001).  
 
 
       
 
 
 
 
 
Figure 5. Human endometriotic epithelial (12ZVK) and stromal (22B) cells. The 12ZVK cells are 
triangular, flat and aggregate closely to each other suggestive of epithelial cell-to-cell contacts. The 
22B cells show a spindle-shaped, elongated, fibroblastoid morphology and some of them have a 
branched cytoplasm. 22B cells often aggregate in parallel clusters when crowded and are scattered 
when their numbers are few. 
 
2.1.3 Primary Endometrial Stromal Cells 
Primary endometrial stromal cells which have been isolated earlier from endometrial 
tissue obtained from a fertile women in their reproductive age after laporoscopy were 
characterized using antibodies against cytokeratin 18 and α-smooth muscle actin. 
They are α-smooth muscle actin positive but cytokeratin 18 negative. 
Morphologically, they show similar properties like those of the T-HESC cell line (Fig. 
6).
T-HESC 
12ZVK 22B 
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Primary Endometrial Stromal Cells 
 
Figure 6. Human endometrial stromal cells show a spindle-shaped, fibroblastoid morphology in vitro. 
They are often scattered when their numbers are few, however, they often aggregate in parallel 
clusters when crowded.   
 
2.2 Cell Culture with Endometrial, Endometriotic Cell Lines and Primary 
Endometrial Stromal Cells 
 
2.2.1 Aseptic Techniques for Cell Culture 
Equipments and reagents were either bought sterile or sterilized in our laboratory. 
Heat-labile solutions were sterilized with filters (pore size 0.22, μm; Millipore). The 
bench surface of the laminar flow was completely cleared and the surface was wiped 
with 70% ethanol. The UV light in the laminar was turned on for 30 minutes. Then the 
hood blower and lights were turned on and the air was allowed to circulate for 20 
minutes before use. The items needed were wiped with 70% ethanol just before 
introducing them into the laminar flow. Latex surgical gloves were worn to avoid 
contaminations and desinfected with 70% ethanol before starting to work which was 
repeated in regular intervals.  
Cell culture media used were supplemented with 1% pen/strep (100X, PAA, Austria) 
and 1% plasmocin (Amaxa) or mycokill (10μg/ml, PAA) in order to avoid microbial 
contaminations like fungi, mycoplasms and bacteria. Transfer and preparations of cell 
culture media in the laminar was done using sterile media flasks and disposable 
pipettes to minimize contamination. When adding (or replacing) medium, care was 
taken not to touch the neck of the culture flasks which were cleaned with sterile 
cotton swabs after medium transfer before putting the flasks into the incubator. 
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2.2.2 Cell Culture Media for Endometrial and Endometriotic Cells 
Generally, media were supplemented with appropriate amounts of serum, glutamine, 
antibiotics and other nutrients. All sterile media were prepared before starting to work 
with cells to avoid contamination and cross-infection during cell culture. All 
procedures for media preparations were carried out in the laminar to ensure maximal 
sterility.  
The purchased ready-to-use media were stored at 4°C and after reconstitution were 
stored at 4°C for a maximum of one month. Before cell culture, appropriate amounts 
of reconstituted media were pre-warmed to 37°C in a water bath for about 20 
minutes. 
• Cell culture medium for primary endometrial stromal cells, endometrial (HES) and  
   endometriotic (12ZVK) epithelial cells: 
   DMEM High Glucose (4.5 g/L) without phenol red (PAA, Austria) 
      + 10% fetal calf serum (FCS) (PAA, Austria) 
      + 1% 100x pen/strep (PAA, Austria) and 1% L-glutamine (PAA, Austria) 
•  Cell culture medium for endometrial stromal cells (T-HESC): 
   DMEM F12 with L-glutamine without phenol red (Invitrogen, U.S.A.) 
      + 10% fetal calf serum (FCS) (PAA, Austria) 
      + 1% 100x pen/strep (PAA, Austria) and 1% Insulin Transferrin Selenium X  
         (Invitrogen, U.S.A.) 
•  Cell culture medium for endometriotic stromal cells (22B): 
      DMEM High Glucose (4.5 g/L) without phenol red 
         + 10% Charcoal/Dextran Treated FCS (Thermo Scientific, U.S.A.) 
         + 1% 100x pen/strep (PAA, Austria) and 1% L-glutamine (PAA, Austria) 
 
2.2.3 Changing Cell Culture Medium 
Cell culture flasks were removed from the CO2 incubator and placed directly in the 
laminar flow. The medium in the cell culture flask was discarded completely and 
replaced with fresh pre-warmed medium every 2-3 days depending upon cell 
confluency. The cap was fixed loosely on the flask so that air can enter into the flask. 
The date of medium change was recorded on the flask and then returned back to the 
CO2 incubator. 
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2.2.4 Passaging or Splitting of Cells 
Cells were passaged regularly at 80% confluency to avoid senescence associated 
with prolonged high cell density. All old medium was discarded, 10 ml pre-warmed 
accutase added and the flask was rotated to achieve a complete coverage of the 
accutase, then the cells were incubated (37°C, 5% CO2) for 5 to 10 minutes. After 
microscopic inspection to ensure complete detachment of cells from the flask, it was 
gently tapped at the sides to release remaining adherent cells. Cells were 
resuspended in 10 ml fresh serum-containing medium to inactivate accutase, and 
then transferred into a 50 ml falcon tube and centrifuged for 5 minutes at 1500 x g. 
The supernatant was discarded and 5 ml of medium was added to re-suspend cell 
pellets. 500 μl to 2000 μl of cell suspension was transferred into a new cell culture 
flask with 25 ml fresh medium. The cell passage number and date of passage were 
documented on the flask. The flask was shaken gently to achieve a uniform cell 
suspension and then taken back into the incubator. 
 
2.2.5 Cryopreservation of Cells   
Cell freezing is essential for long-term storage of cells. The cell pellet obtained by the 
process of passaging (2.2.4) was resuspended in medium Filocethplus (Procryoptect, 
Germany). The cryo-medium reduced the freezing point of media and also allowed a 
slower cooling rate, greatly reducing the risk of crystal formation which can damage 
the cells and cause cell death. Aliquots of 1 ml cell suspensions were transferred into 
cryotubes which were then stored at -80°C overnight for slow cooling before storage 
in liquid nitrogen. 
 
2.2.6 Thawing Frozen Cells 
Proper thawing of cryopreserved cells is crucial to ensure viability and functionality of 
the cells. The thawing process is done very quickly to ensure that a high proportion of 
the cells survive the procedure. 
Cryotubes were taken out of the liquid nitrogen and immediately placed into a 37°C 
water bath. The contents of the cryotube were transferred to a 15 ml falcon tube with 
9 ml pre-warmed fresh medium. The cell suspension was centrifuged (1500 x g, 5 
min) to remove the Filoceth. After centrifugation, the liquid phase was aseptically 
discarded without disturbing the cell pellet. The remaining pellet was gently 
resuspended with 1 ml medium and then transferred into a 75 cm² or 150 cm² cell 
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culture flask containing 14 ml or 24 ml medium, respectively. Mycokill AB (PAA, 
Austria) was added into the flasks to protect cells from contamination by 
microorganisms. The cell culture flasks were placed in an incubator (37°C, 5% CO2). 
 
2.2.7 Counting  and Seeding of Cells 
Counting of cells was done by adding accutase to the plates (500 μl for 6-well plates, 
200 μl for 24-well plates) and then incubated in the incubator for 5-10 minutes. After 
complete detachment, equal volumes of fresh medium were added and cells were 
resuspended thoroughly by pipetting up and down. 10 μl of the cell suspension was 
transferred to a CASY tube with 10 ml CASY-ton solution and mixed well. 
Measurement of the cells was done with the CASY-counter (Schaerfe System, 
Germany). 
Cells were seeded onto cell culture plates. In my experiments, 2x104 cells were 
seeded into each well of a 96-well plate (Corning, USA) with 100 μl media containing 
10% FCS; 4x104 cells were seeded into each well of a 24-well cell culture plate (TPP, 
Switzerland) with 1 ml medium containing 10% FCS, and 2x105 to  4x105 cells were 
seeded into each well of a 6-well plate (TPP, Switzerland) with 4 ml medium 
containing 10% FCS. The plates were incubated overnight (37°C, 5% CO2).  
 
2.2.8 Cell Starvation and Stimulation with Recombinant Human TGF-βs 
After overnight culturing, the old medium was discarded from the plates. Fresh 
medium containing 1% FCS was added to starve the cells for an appropriate time 
(37°C, 5% CO2).  
Cell stimulation was done with rh-TGF-β1 and rh-TGF-β2 (Promokine, Germany). 
Media containing 1% FCS with 10 ng/ml TGF-β1 or TGF-β2, respectively, were 
prepared. From the plates with the starved cells, the old medium was removed and 
fresh medium with 10 ng/ml TGF-β1 or TGF-β2 was added into the appropriate wells, 
respectively. PBS was added into the control well and then cultured for an 
appropriate time (37°C, 5% CO2). 
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2.3 Analysis of PAI-1 and Inhibin B Secretion  
To analyze how TGF-β1 or TGF-β2 influence PAI-1 or inhibin B secretion, PAI-1 or 
inhibin B ELISAs were performed (Fig. 7) and repeated in three independent 
experiments.  
 
2.3.1 Culturing of Cells with Specific Intracellular Pathway Inhibitors 
Seven inhibitors targeting different pathways were used to investigate the pathways 
that might be involved in TGF-β signaling. 
•  Specific Inhibitor of Smad3: SiS3 (Calbiochem, USA; Masatoshi et al., 2005) 
•  TGF-β receptor type I inhibitor: LY364947 (Sigma-Aldrich, USA; Sawyer et  
  al., 2003) 
•  BMP inhibitor: LDN 193189 (Stegment, USA; Yu et al., 2008) 
•  Activin R1A/ALK-2 inhibitor: FC Chimera (R&D Systems, USA; Wu and Hill, 
  2009) 
 •  BMPR-1A/ALK-3 inhibitor: FC Chimera (R&D Systems, USA; Wu and Hill, 
  2009) 
 •  BMPR-1B/ALK-6 inhibitor: FC Chimera (R&D Systems, USA; Kawabata et  
  al., 1998) 
 •  IgG1 inhibitor: FC Chimera (R&D Systems, USA) 
 
Culture of 4x105 cells in 6-well plates with 4ml medium (10% FCS) 
Add TGF-β1 or TGF-β2 (10ng/ml), respectively 
Collect supernatants Cell Counting 
Inhibin B or PAI-1 ELISA 
 8 hours 
over night
Replace medium (10% FCS) to medium (1% FCS) 
 72 hours 
Figure 7. Scheme for analyzing secretion of inhibin B or PAI-1  
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Culture media with 1% FCS containing either 5 μM LY364947, 2μM SiS3, 5 μM BMP 
inhibitor, 10 μg/ml ALK-2 inhibitor, 4 μg/ml ALK-3  inhibitor,  6 μg/ml ALK-6 inhibitor 
and 2 μg/ml IgG1 inhibitor, respectively, were prepared. Media in 6-well plates was 
discarded. Then 2000 μl media with or without inhibitors was added into the 
corresponding wells, respectively. After cells were incubated for 2 hours (37°C, 5% 
CO2), they were stimulated with 10 ng/ml TGF-β1 or TGF-β2 (Fig. 8). 
 
 
2.3.2 Supernatants Collection and Cell Quantification 
One ml of supernatant was collected from each well and 7 μl Protease Inhibitor 
cocktail (Sigma-Aldrich, USA) was added to protect against proteases. After 
vortexing and centrifugation (5000 x g for 10 min at 4°C), 750 μl of the supernatant 
from each tube was collected and stored as aliquots at -20°C. Quantification of cells 
was done as described (2.2.7).  
 
2.3.3 PAI-1 ELISAs 
The PAI-1 levels in the supernatants were quantitated by use of the TECHNOZYM® 
PAI-1 Antigen ELISA Reagent Kit (Technoclone, Germany).  
The kit contains: 
• Coating Antibody - a vial with 500μg lyophilized monoclonal  anti-PAI-1 
• Conjugate monoclonal anti-PAI-1 POX, dyed blue. 
Seed 4x105 cells in 6-well plates with 4 ml medium (10% FCS) 
Add inhibitors
 
Add TGF-β1 or TGF-β2 (10ng/ml), respectively 
Collect supernatants Cell Counting 
PAI-1 ELISA 
 6 hours 
over night
Replace medium (10% FCS) to medium (1% FCS) 
 2 hours 
 72 hours 
Figure 8. Scheme for analyzing secretion of PAI-1  
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• Calibrator- 0.5ml lyophilized 
 
Preparation of Reagents 
Reagents were brought to room temperature before use. 
• Coating Buffer -2.93 g NaHCO3, 1.59 g Na2CO3 diluted with distilled water to a 
final volume of 1 liter, pH=9.6 
• Phosphate buffered saline (PBS, 1x) - 8.0 g NaCl, 0.2 g KH2PO4, 1.44 g 
Na2HPO4·2H2O,0.2 g KCl, dissolved in distilled water to a final volume of 1 liter, 
pH=7.4 
• Washing  Buffer - 0.5% Tween 20 (Sigma, Germany) in 1x PBS 
• Incubation Buffer - 1% bovine serum albumin (BSA, Roth, Germany) +   
 0.01% thimerosal in PBS 
• TMB substrate (Calbiochem, Germany) 
• Stop Solution - 2M sulfuric acid 
 
Test Preparation 
• Coating Plate 
After reconstitution of the coating antibody (500 μl distilled water), 100 μl were mixed 
thoroughly with 10 ml coating buffer. Then 100 μl were pipetted into each well of a 
96-well plate (Nunc Maxisorp, Denmark) and the sealed plate was incubated over 
night at 4°C for at least 16 hours. 
• Reconstituting Calibrator  
The calibrator was reconstituted with 500 μl distilled water (stock solution of 132.7 
ng/ml), mixed for 10 seconds and then incubated at room temperature for at least 15 
minutes with gentle agitation. 5 microcentrifuge tubes were labeled and 100 μl 
incubation buffer was added to each tube. Serial dilutions of the 100 μl stock solution 
were prepared (66.35 ng/ml, 33.18 ng/ml, 16.59 ng/ml, 8.29 ng/ml and 4.15 ng/ml). 
The last tube contained only incubation buffer which served as a blank (0 ng/ml). 
• Supernatant Samples  
Supernatants were removed from -20°C and put at room temperature. Supernatants 
from HES, 12ZVK, THESC, 22B and primary endometrial stromal cells were diluted 
25-fold, 50-fold, 75-fold, 100-fold and 75-fold with incubation buffer, respectively.   
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• Diluting Conjugate Solution 
The conjugate solution was stored as a 50x concentrated solution. One part of the 
conjugate solution (v/v) was diluted with 50 parts (v/v) of the incubation buffer.  
Assay Procedure 
All samples, standards and controls were assayed in duplicate.  
1. The samples and the reagents were prepared as described above.  
2. 100 μl incubation buffer was added into each well and the plate incubated at 
37°C for 1 hour. 
3. The incubation buffer was discarded and the plate washed with 200 μl wash 
buffer three times. The wash buffer was discarded. 
4. 25 μl standard or sample diluted with 75 μl incubation buffer was added into 
each well and the plate incubated at 37°C for 1 hour. 
5. All liquids were discarded and 100 μl conjugate working solution was added 
into each well. The plate was incubated at 37°C for 1 hour. 
6. All wells were emptied thoroughly and washed with 200 μl wash buffer three 
times. 
7. 100 μl TMB substrate was added into each well and the plate incubated at 
room temperature for 10 minutes protected from light.  
8.  100 μl Stop Solution was added to each well. 
9.  OD values at 450 nm were measured on a microplate reader, with a reference 
wavelength set at 620 nm. 
 
2.3.4 Inhibin B ELISAs 
Inhibin B levels in the supernatant were measured by using inhibin B Enzyme 
immunoassay ELISA kits (RayBiotech, USA) detecting inhibin beta B, activin B and 
activin AB. 
The kits contains: 
• Inhibin B Microplate - A 96-well polystyrene microplate (12 strips of 8 wells) 
coated with anti-rabbit secondary antibody against human inhibin B 
• Anti-inhibin B polyclonal antibody - A polyclonal antibody against human inhibin 
B with preservatives 
• Standard Inhibin B Peptide - A buffered protein with preservatives 
• Biotinylated Inhibin B peptide - A buffered protein with preservatives 
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• Positive control - A cell culture medium sample with an expected signal between 
10% to 30% of total binding 
• Wash Buffer Concentrate - A 20x solution of buffered surfactant with 
preservatives 
• Assay Diluent A - Contains 0.09% sodium azide as preservative. Diluent for 
standards and serum or plasma samples 
• Assay Diluent B - A 5x diluent buffer for standards, cell culture media or other 
sample types 
• HRP-Streptavidin Concentrate - 400x HRP-conjugated Streptavidin 
• TMB One-Step Substrate Reagent - 3, 3’, 5,5’- tetramethylbenzidine (TMB) in 
buffered solution 
• Stop Solution - 0.2 M sulfuric acid 
Reagent Preparation 
All kit reagents were kept on ice during reagent preparation. The plate was 
equilibrated to room temperature. 
• Assay Diluent B - 15 ml of assay diluent B concentrate was diluted with 60 ml 
deionized water forming 1x assay diluent B. 
• Anti-inhibin B Polyclonal antibody - 5 μl of anti-inhibin B polyclonal antibody was 
added to 50 μl assay diluent B (1x), mixed gently and placed on ice. 
• Biotinylated Inhibin B peptide - 5 μl of biotinylated inhibin B peptide was added to 
5 ml assay diluent B (1x) to a final concentration of 100 pg/ml, mixed gently and 
placed on ice. 
- 10x biotinylated inhibin B peptide was prepared by adding 2 μl of biotinylated inhibin 
B peptide to 18 μl of assay diluent B. 
• Standards - Six microcentrifuge tubes were labeled (10,000 pg/ml, 100 pg/ml, 10 
pg/ml, 1 pg/ml and 0 pg/ml). Then 450 μl 1x biotinylated inhibin B peptide solution 
was added to each tube, except to the tube labeled 10,000 pg/ml. In this tube 
(10,000 pg/ml) 8 μl of standard inhibin B peptide was added with 792 μl of 1x 
biotinylated inhibin B peptide solution and mixed thoroughly. This was inhibin B stock 
solution (10,000 pg/ml inhibin B, 100 pg/ml biotinylated inhibin B) and served as the 
first standard. Then 50 μl of the first standard solution was used to produce dilution 
series (100 pg/ml, 10 pg/ml and 1 pg/ml). The final tube (0 pg/ml inhibin B, 100 pg/ml 
biotinylated inhibin B) served as the zero standard.  
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• Positive Control - 100 μl of the positive control was diluted with 101 μl of 1x Assay 
Diluent B. Also 2 μl of 10x biotinylated inhibin B peptide was added and mixed 
thoroughly.  
• Wash Buffer Concentrate - 20 ml Wash Buffer Concentrate was diluted with 380 
ml deionized water (1x Wash Buffer).  
• HRP-Streptavidin Concentrate - The HRP-Streptavidin concentrate was diluted 
400-fold with 1x Assay Diluent B. 
• Supernatant Sample - Supernatants stored at -20°C were thawed at room 
temperature. 247.5 μl of each sample was added to 2.5 μl of 10x diluted biotinylated 
inhibin B peptide solution and mixed thoroughly before use. 
 
Assay Procedure  
All reagents and samples were kept on ice during reagent preparation steps.  
All samples, standards and controls were assayed in duplicate.  
1. Reagents and samples were prepared as described above. 
2. 100 μl anti-inhibin B antibody was added to each well and the plate incubated 
overnight at 4°C. 
3. Each well was aspirated and washed with 300 μl wash buffer four times. 
4. 100 μl standard, control or sample was added to each well and the plate 
incubated for 2.5 hours on an orbit shaker at RT. 
5. Each well was aspirated and washed with 300 μl wash buffer four times.  
6. 100 μl of the prepared Streptavidin Solution was added and the plate  
incubated for 45 minutes on an orbit shaker at RT. 
7. 100 μl TMB Substrate Solution was added to each well and the plate 
incubated for 30 minutes on an orbit shaker at RT protected from light. 
8. 50 μl Stop Solution was added to each well. 
9. OD values at 450 nm were measured on a microplate reader. 
 
2.4 Phospho-Smad3 ELISAs 
To analyze the affect of TGF-β1 or TGF-β2 on phosphorylation of Smad3, cell lysates 
were collected from all cell lines and primary endometrial stromal cells.  
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2.4.1 Collection of Cell Lysates for Phospho-Smad3 ELISAs 
1. 4x105 cells were seeded in 6-well plates with 4 ml medium (10% FCS) and the 
plate incubated overnight at 37°C. 
2. The medium (10% FCS) was replaced with medium (1% FCS) and the plate 
incubated for 6 hours at 37°C. 
3. SiS3 (3 μM) and Ly364947 (5 μM) inhibitors, respectively, were added and the 
plate incubated for 2 hours at 37°C. 
4. TGF-β1 or TGF-β2 (10ng/ml), respectively, were added and the plate 
incubated for 30 minutes at 37°C. 
5. Media were aspirated from each well and the plate washed once with 4 ml/well 
ice cold PBS. 
6. 400 μl 1x Cell Lysis Buffer was added to each well and the plate incubated for 
10 minutes on an orbit shaker at RT. 
7. The cell lysates were collected. 
8. Phospho-Smad3 ELISA was performed. 
 
2.4.2 Phospho-Smad3 ELISA Assay Procedure 
The phosphorylated human Smad3 (Ser423/425) in cell lysates was measured by 
using The InstantOneTM ELISA Reagent Kit (eBioscience, USA).  
The kit contains: 
• InstantOneTM ELISA Assay Plate - A 96-well polystyrene microplate 
• Phospho-Smad3 (Ser423/425) Capture Antibody Reagent - Capture antibody 
reagent which will be mixed in equal parts with the Detection Antibody Reagent to 
yield the Antibody Cocktail (ELISA antibody sandwich pair). 
• Phospho-Smad3 (Ser423/425) Detection Antibody Reagent - Detection antibody 
reagent which will be mixed in equal parts with the Capture Antibody Reagent to yield 
the Antibody Cocktail (ELISA antibody sandwich pair). 
• Positive Control Cell Lysate - The Positive Control from various cell types is 
supplied lyophilized. 
• Enhancer Solution - The Enhancer Solution is supplied as a concentrate.  
• Cell Lysis Buffer - The Cell Lysis Buffer is a combination of the Cell Lysis Buffer 
and Enhancer Solution to yield a versatile Cell Lysis Mix that can be applied to many 
cells and tissues. The Cell lysis buffer (5x) contains a combination of detergents, 
phosphatase inhibitors, salt and buffers.  
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• Wash Buffer - The Wash Buffer is supplied as a 10x concentrate. 
• Detection Reagent (TMB substrate)  
• Stop Solution - The acidic Stop Solution is used for stopping the HRP-mediated 
colorimetric conversion. 
 
Reagents Preparation 
All reagents were brought to room temperature before use. 
• InstantOneTM ELISA Assay Plate - Rinse plate with double distilled water prior 
performing the assay. 
• Antibody Cocktail - The Antibody Cocktail was made by mixing 200 μl Capture 
Antibody Reagent with 200 μl Detection Antibody Reagent. Then 50 μl was added to 
each well. 
• Positive Control Cell Lysate - The Positive Control Cell Lysate was reconstituted 
with 250 μl of double distilled water.  
• Wash Buffer - The Wash Buffer (10x) was diluted to 1x with double distilled water.  
• Enhancer Solution - The Enhancer Solution was supplied as a concentrate. It was 
warmed to 37°C and mixed prior to use.  
• Cell Lysis Buffer - The Cell Lysis Buffer (5x) was prepared by mixing 900 μl Cell 
Lysis Buffer (5x) with 100 μl Enhancer Solution. The resulting solution was diluted 
with water to 1x Cell lysis buffer and was used to directly lyse the cells after 
aspiration of the medium.  
• Detection Reagent - Warm to room temperature before use. 
• Sample preparation - Cell lysates were collected earlier as described. 
 
Assay Procedure 
All reagents and samples were brought to room temperature before use. All samples 
and controls were assayed in duplicate. The procedure of the assay is described 
below 
1. Reagents and samples were prepared as described earlier. 
2. The desired number of InstantOne microplate strips was determined.  
3. 50 μl sample lysates or controls were added into each well.  
4. 50 μl of freshly prepared antibody cocktail was added to each of the test wells 
and the plate incubated for 1 hour on an orbit shaker at RT. 
5. The liquid phase was discarded and wells were washed with 200 μl wash 
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buffer three times. 
6. 100 μl Detection Reagent was added into each well and the plate was  
incubated for 30 minutes at RT protected from light. 
7. 100 μl Stop Solution was added to each well. 
8. The OD values at 450 nm were measured on a microplate reader, with the 
correction wavelength at 570 nm. 
 
2.5 Cell Apoptosis Assays 
Cell apoptosis assays were done to investigate whether or not the effect of TGF-β1 
or TGF-β2 on cell numbers is through apoptosis and which apoptotic pathways might 
be involved. 
 
2.5.1 Stimulation of Cells with TGF-β1 or TGF-β2 
Cells were treated with or without TGF-β1 or TGF-β2 (10 ng/ml) and with or without 
the SiS3 (3 μM) and Ly364947 (5 μM) inhibitors, respectively. Staurosporine (0.1 μM, 
Promokine, USA) was used as a positive control while growth medium alone was 
used as blank. Cells were treated for 24 hours and then apoptosis assays were 
performed. The apoptotic parameters investigated included quantification of 
phosphatidylserine on the outer surface of the cell membrane, measurement of the 
inner mitochondrial membrane potential and quantification of Cysteinyl-asparate-
specific proteases 3/7 (Caspase 3/7) levels (Fig. 9).  
 
 32
 
 
2.5.2 Phosphatidylserine Apoptosis ELISA 
The effect of the TGF-βs on translocation of phosphatidylserine to the outer surface 
of the cell membrane was measured by the Cell meterTM Phosphatidylserine 
Apoptosis assay Kit (AAT Bioquest, USA).  
The kit contains:  ApopxinTM Orange(100X Stock solution); Assay Buffer (10ml). 
 
Preparation of Reagents 
All reagents were brought to room temperature before use. 
•  ApopxinTM orange assay working solution –10 μl of ApopxinTM Orange was 
added into 1 ml Assay Buffer and mixed well. The mixture was protected from light. 
Always a fresh mixture was prepared prior to use. 
 
 
a) 2x104 cells in 96-well black plates with 100 μl medium (10% FCS) for 
phosphatidylserine apoptosis assay 
OR 
b) 4x104 cells in 96-well black plates with 100 μl medium (10% FCS) for 
mitochondrial membrane potential assay  
OR 
c) 2x104 cells in 96-well black plates with 90 μl medium (10% FCS for 
Caspase 3/7 apoptotis assay 
Add inhibitors, respectively 
- LY364947(5 μM) 
- SiS3 (3 μM) 
Add TGF-β1 or TGF-β2 (10ng/ml) or staurosporine (0.1 μM)  
Perform Apoptosis ELISAs 
Incubate 6 hours at 37°C
Incubate overnight at 37°C  
Starve cells with 1% FCS medium 
Incubate 8 hours at 37°C
Incubate 2 hours at 37°C
Incubate 24 hours at 37°C 
Figure 9. Scheme of treatment of cells for Apoptosis ELISAs
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Assay Procedure 
A 96-well plate (Corning, USA) with cells treated as indicated (2.5.1) was removed 
from the incubator after 24 hours incubation. All samples and controls were assayed 
in duplicate. The procedure is described below  
1. Reagents and samples were prepared as described above. 
2. The 96-well plate with cells treated was removed as indicated (2.5.1). 
3. 100 μl of freshly prepared ApopxinTM orange assay working solution was 
added to each of the test wells and the plate incubated for 1 hour at RT 
protected from light. 
4. The fluorescence intensity was measured at Excitation/Emission of 540/590 
nm.  
 
2.5.3 Mitochondrial Membrane Potential Apoptosis ELISA 
The effect of the TGF-βs on the loss of the mitochondrial membrane potential by the 
cells was measured by the Cell meterTM Mitochondrial Membrane Potential Apoptosis 
assay Kit (AAT Bioquest, USA).  
The kit contains: MitoLiteTM Orange (200X Stock solution);  Assay Buffer A (50 ml); 
Assay Buffer B (25 ml). 
 
Preparation of Reagents 
All reagents were brought to room temperature before use. 
•  MitoLiteTM Orange dye-loading solution – 50 μl of MitoLiteTM Orange was added 
to 10 ml Assay Buffer A and mixed well. The unused 200x MitoLiteTM Orange was 
aliquoted and stored at -20°C.  
• Assay Buffer B - Ready to use. 
Assay Procedure 
A 96-well plate (Corning, USA) with cells treated as indicated (2.5.1) was removed 
from the incubator after 24 hours of incubation. All samples and controls were 
assayed in duplicate. The procedure is described below 
1. Reagents and samples were prepared as described above. 
2. The 96-well plate with cells treated was removed as indicated (2.5.1). 
3. The test wells were emptied and 100 μl of freshly prepared MitoLiteTM Orange 
dye-loading solution was added to each of the test wells. The plate was 
incubated for 30 minutes at RT protected from light. 
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4. 50 μl of Assay Buffer B was added to each of the test wells. 
5. The fluorescence intensity was measured at Excitation/Emission= 540/590 
nm. 
 
2.5.4 Caspase 3/7 Activity Apoptosis ELISA 
The effect of the TGF-βs on Caspase 3/7 activation by the cells was measured by the 
Cell meterTM Caspase 3/7 Activity Apoptosis assay Kit (AAT Bioquest, USA).  
The kit contains: Caspase 3/7 Substrate (200x Stock solution);  Assay Buffer 
(20ml). 
Preparation of Reagents 
All reagents were brought to room temperature before use. 
•  Caspase 3/7 assay loading solution - 50 μl of Caspase 3/7 Substrate was added 
to 10 ml Assay Buffer and mixed well. The unused 200x Caspase 3/7 substrate and 
assay buffer were aliquoted and stored at -20°C.  
 
Assay Procedure 
The 96-well plate (Corning, USA) with cells treated as indicated (2.5.1) was removed 
from the incubator after 24 hours of incubation. All samples and controls were 
assayed in duplicate. The procedure is described below 
1. Reagents and samples were prepared as described above. 
2. The 96-well plate with cells treated was removed as indicated (2.5.1). 
3. 100 μl of freshly prepared Caspase 3/7 assay loading solution was added to 
each of the test wells. The plate was incubated for 1 hour at RT protected from 
light. 
4. 50 μl of Assay Buffer B was added to all wells. 
5. The fluorescence intensity was measured at Excitation/Emission of 350/450 
nm.  
 
2.6 Cell Surface ELISAs 
The Cell surface ELISA was used to investigate the effects of TGF-β1 or TGF-β2 on  
cell surface expression of TβRIII in HES, T-HESC, 12ZVK, 22B and primary 
endometrial stromal cells. 
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2.6.1 Preparation of Cells  
The cells were prepared as described below 
1. A 24-well plate was coated with TGF-β1 or TGF-β2 (10 ng/ml), respectively 
and the plate incubated overnight at 4°C.  
2. PBS was aspirated from each well and the plate washed once with ice cold 
PBS, 4 ml per well.  
3.  4x104 cells were seeded in a 24-well plate with 1 ml medium (10% FCS) and 
incubated for 48 hours at 37°C, 5% CO2. 
4. The Cell-Surface ELISA was performed. 
 
2.6.2 Cell Surface ELISA Procedure 
Preparation of Reagents 
• Phosphate buffered saline (PBS) - 8.0 g NaCl, 0.2 g KH2PO4, 1.44 g 
Na2HPO4·2H2O, 0.2 g KCl, diluted with distilled water to a final volume of 1 liter, 
pH=7.4 
• 4% paraformaldehyde - 4.0 g paraformaldehyde (ROTH, Germany) were 
dissolved in 10ml PBS (10X) and diluted with distilled water to a final volume of 
100ml, pH=7.3 
• Binding buffer - 2.86 g HEPES, 8.18 g NaCl and 0.37 g KCl, diluted with distilled 
water to a final volume of 1 liter, pH=7.4 
• 5% BSA in Binding buffer - 2.5 g BSA in 50ml Binding buffer prepared above. 
Freshly made prior to the experiment. 
• Primary antibody - Rabbit TβRIII monoclonal antibody (R&D Systems, USA). 
Diluted with 5% BSA binding buffer (1:200) 
• Secondary antibody - Rabbit Anti-Goat IgG/HRP (DAKO, USA). Diluted with 5% 
BSA binding buffer (1:2000) 
• TMB substrate (Calbiochem, Germany) 
• Stop Solution - 0.18N sulfuric acid 
 
Assay Procedure 
All samples and controls were assayed in duplicate. The procedure of the assay is 
summarized below 
1. Reagents and samples were prepared as described above. 
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2. A 24-well plate with cells treated as indicated (2.6.1) was put on ice. 
3. The medium (10% FCS) was aspirated from each test well. 
4. All wells were washed once with 1 ml ice cold binding buffer.  
5. Cells were fixed with 500 μl ice cold 4% paraformaldehyde and the plate was 
incubated for 15 minutes at RT. 
6. Wells were washed with 1 ml ice cold binding buffer three times. 
7. Wells were blocked with 500 μl of 5% BSA binding buffer. The plate was 
incubated for 1 hour at RT. 
8. 300 μl Primary antibody was added to each well. The plate was incubated for 
1 hour at RT. 
9. Wells were washed with 1 ml ice cold binding buffer three times.  
10.  300 μl Secondary antibody was added to each well. The plate was incubated 
for 1 hour at RT protected from light. 
11.  Wells were washed with 1 ml ice cold binding buffer three times.  
12.  300 μl TMB Substrate was added to each well. The plate was incubated for 1 
hour at RT. 
13.  300 μl Stop Solution was added to each well. 
14.  OD values at 450 nm were measured on a microplate reader, with the    
    correction wavelength at 570 nm. 
 
2.7 TGF-β1 and TGF-β2 ELISA 
The TGF-β1 or TGF-β2 ELISA was performed to investigate the pathways after 
treatment of cells with TGF-β1 or TGF-β2. All cell lines and primary endometrial 
stromal cells were treated with TGF-β1 or TGF-β2 (10 ng/ml), respectively. Then cell 
supernatants were collected after 48 hours upon TGF-β1 or TGF-β2 treatment to 
quantitate TGF-β1 or TGF-β2 (Fig. 10).  
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2.7.1 TGF-β1 or TGF-β2 ELISA Reagent Preparation 
The TGF-β1 and TGF-β2 levels in the supernatants was measured by use of the 
TGF-β1 and TGF-β2 DuoSet Development Kits (R&D Systems, USA). 
 
a) TGF-β1 DuoSet Development Kit contains: 
• Capture Antibody - 360 μg/ml of mouse anti-TGF-β1 when reconstituted with 1 ml 
PBS 
• Detection Antibody - 54 μg/ml of biotinylated chicken anti-human TGF-β1 when 
reconstituted with 1ml Reagent Diluent 
• Standard - 140 ng/ml of recombinant human TGF-β1 when reconstituted with 0.5 
ml Reagent Diluent 
• Streptavidin-HRP - 1.0 ml of streptavidin conjugated to horseradish-peroxidase 
 
 
Culture 4x105 cells in 6-well plates with 4 ml medium (10% FCS) 
Add TGF-β1 or TGF-β2 (10ng/ml), respectively 
Collect supernatants Cell Counting 
TGF-β1 or TGF-β2 ELISAs 
 Incubate 8 hours at 37°C  
Incubate over night at 37°C  
Replace medium (10% FCS) to medium (1% FCS) 
 Incubate 24 hours at 37°C  
Figure 10. Scheme for analyzing the collected supernatants for TGF-β1 or TGF-β2 ELISAs 
 
Replace medium (1% FCS) with new medium (1% FCS) 
Incubate 24 hours at 37°C  
Incubate 24 hours at 37°C  
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Preparation of Reagents 
All reagents were brought to room temperature before use. 
• Phosphate buffered saline (PBS) - 137mM NaCl, 1.5mM KH2PO4, 8.1mM 
Na2HPO4·2H2O, 2.7mM KCl, diluted with distilled water to a final volume of 1 liter, 
pH=7.4, 0.2μm filtered 
• Wash Buffer - 0.05% Tween 20 (Sigma, Germany) in PBS, pH=7.2-7.4  
• Block Buffer - 5% Tween 20 (Sigma, Germany) in PBS  
• Reagent Diluent - 1.4% delipidized BSA, 0.05 % Tween 20 (Sigma, Germany) in 
PBS  pH=7.2-7.4, 0.2 μm filtered 
• TMB substrate (Calbiochem, Germany), Stop Solution (2 N sulfuric acid), 1N HCl 
(Roth, Germany), 1N NaOH (Roth, Germany) and 0.5M HEPES (Roth, Germany) 
 
Test Preparation 
•  Reconstituting Capture Antibody 
Reconstitution of the capture antibody was reconstituted with 1 ml PBS, aliquoted 
and stored at -80°C. One aliquot was diluted to a working concentration of 2.0 μg/ml 
in PBS and 100 μl of this dilution was pipetted into each well of a 96-well ELISA plate 
(Nunc Maxisorp, Denmark). Then the plate was incubated over night (at least 16 
hours) at 4°C.  
 
• Reconstituting Detection Antibody  
The detection antibody was reconstituted with 1 ml Reagent Diluent, aliquoted and 
stored at -80°C. One aliquot was diluted to a working concentration of 300 ng/ml in 
Reagent Diluent and 100 μl of this dilution was pipetted into each well of a 96-well 
ELISA plate (Nunc Maxisorp, Denmark). 
• Reconstituting Standard  
The standard was reconstituted by mixing for 10 seconds with 0.5 ml Reagent Diluent 
(stock solution of 140 ng/ml), and kept at room temperature for at least 15 minutes 
with gentle agitation prior making dilutions. Aliquots were made and stored at -80°C. 
One aliquot was diluted to a working concentration of 2000 pg/ml in Reagent Diluent. 
Meanwhile, 7 microcentrifuge tubes were labeled and then 500 μl Reagent Diluent 
was added to each tube. Then 500μl stock solution was used to make serial dilutions 
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(1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml and 31.25 pg/ml). The last 
tube contained only Reagent Diluent served as a standard of 0 pg/ml. 
b) TGF-β2 DuoSet Development Kit contains: 
• Capture Antibody - 360 μg/ml of mouse anti-TGF- β2 after reconstitution with 1 ml 
PBS 
• Detection Antibody - 27 μg/ml of biotinylated goat anti-human TGF-β2 when 
reconstituted with 1 ml PBS 
• Standard - 70 ng/ml of recombinant human TGF-β2 when reconstituted with 0.5 ml 
Reagent Diluent 
• Streptavidin-HRP - 1 ml streptavidin conjugated to horseradish-peroxidase 
Preparation of Reagents 
All reagents were brought to room temperature before use. 
• Phosphate buffered saline (PBS) - 137 mM NaCl, 1.5 mM KH2PO4, 8.1 mM 
Na2HPO4·2H2O, 2.7 mM KCl, diluted with distilled water to a final volume of 1 liter, 
pH=7.4, 0.2 μm filtered 
• Wash Buffer - 0.05% Tween 20 (Sigma, Germany) in PBS, pH=7.2-7.4  
• Block Buffer - 5% Tween 20 (Sigma, Germany) in PBS  
• Reagent Diluent - 1% BSA in PBS, pH=7.2-7.4, 0.2 μm filtered 
• TMB substrate (Calbiochem, Germany), Stop Solution (1N sulfuric acid), 1N HCl 
(Roth, Germany), 1N NaoH (Roth, Germany) and 0.5M HEPES (Roth, Germany) 
 
Test Preparation 
•  Reconstituting Capture Antibody 
The capture antibody was reconstituted with 1 ml PBS, aliquoted and stored at -
80°C. One aliquot was diluted to a working concentration of 2.0 μg/ml in PBS and 
100 μl of this dilution was pipetted into each well of a 96-well ELISA plate (Nunc 
Maxisorp, Denmark). Then the plate was incubated over night (at least 16 hours) at 
4°C.  
 
• Reconstituting Detection Antibody  
The detection antibody was reconstituted with 1 ml Reagent Diluent, aliquoted and 
stored at -80°C. One aliquot was diluted to a working concentration of 150 ng/ml in 
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Reagent Diluent and 100 μl of this dilution was pipetted into each well of a 96-well 
ELISA plate (Nunc Maxisorp, Denmark). 
 
• Reconstituting Standard  
The standard was reconstituted by mixing for 10 seconds with 0.5 ml Reagent Diluent 
(stock solution of 70 ng/ml), and kept at room temperature for at least 15 minutes 
with gentle agitation prior making dilutions. Aliquots were made and stored at -80°C. 
One aliquot was diluted to a working concentration of 2000 pg/ml in reagent diluent. 
Meanwhile, 7 microcentrifuge tubes were labeled and then 500 μl reagent diluent 
was added to each tube. Then 500 μl stock solution was used to make serial dilutions 
(1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml and 31.25 pg/ml). The last 
tube contained only reagent diluent served as a standard of 0 pg/ml. 
 
• Reconstituting Streptavidin-HRP for TGF-β1 and TGF-β2 ELISAs 
The Streptavidin-HRP was diluted in Reagent Diluent (1:200). 
 
• Activation of latent TGF-βs for Both TGF-β1 and TGF-β2 ELISAs 
Supernatants from HES, 12ZVK, T-HESC, 22B and primary endometrial stromal cells 
(Fig. 10) were activated by HCl at room temperature. 100 μl supernatant sample and 
3.5 μl HCl was added into each microcentrifuge tube, vortexed, placed on ice and 
incubated for 1 hour at 4°C. Neutralization was done by adding 7 μl NaOH and 9 μl 
HEPES, after vortexing thoroughly, 1 μl was taken from each tube for pH testing 
using a pH paper.  
 
2.7.2 TGF-β1 and TGF-β2 ELISAs Assay Procedure 
The same assay procedure was used for TGF-β1 and TGF-β2 ELISAs after 
respective reagent preparations as described.  
All samples, standards and controls were assayed in duplicate. The procedure of the 
assay is summarized below 
1. Reagents and samples were prepared as described above. 
2. The Capture Antibody was also prepared as described above. 
3. 100 μl diluted Capture Antibody was added into each well. The plate was 
incubated overnight at 4°C.   
4. Test wells were emptied and washed with 400 μl wash buffer three times. 
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5. 300 μl block buffer was added into each well. The plate was incubated for 1 
hour at RT. 
6. Test wells were emptied and washed with 400 μl wash buffer three times. 
7. 100 μl standard or sample or controls was added and the plate incubated for 2 
hours at RT. 
8. Test wells were emptied and washed with 400 μl wash buffer three times. 
9. 100 μl diluted Detection Antibody was added into each well. The plate was 
incubated for 2 hours at RT.  
10. Test wells were emptied and washed with 400 μl wash buffer three times. 
11. 100 μl diluted Streptavidin-HRP was added into each well. The plate was 
incubated for 20 minutes at RT protected from light.  
12. Test wells were emptied and washed with 400 μl wash buffer three  times. 
13. 100 μl TMB substrate was added into each well. The plate was incubated for 
20 minutes at RT protected from light. 
14.  100 μl Stop Solution was added to each well. 
15.  OD values at 450 nm were measured on a microplate reader with the 
reference wavelength at 570 nm. 
 
2.8 Characterization of Endometrial and Endometriotic Cells 
Purity of endometrial and endometriotic cells during the cell culture was assessed by 
morphological analysis and by expression analysis with cytokeratin 18 and α-smooth 
muscle actin monoclonal antibodies using immunofluorescence and Western blotting 
assays. Characterization was done to assess the purity of stromal or epithelial cells  
 
2.8.1 Characterization of Endometrial and Endometriotic Cells by 
Immunofluorescence 
The purity of endometrial and endometriotic epithelial cell cultures was characterized 
by indirect immunofluorescence using cytokeratin18 monoclonal antibody (Epitomics; 
Fig. 11).  
 42
 
 
2.8.1.1 Preparation of Cells for Immunofluorescence Assay 
After counting, 6x104 cells were seeded into each well of a 24-well Imaging Plate FC 
(Zell-Kontact, Germany), designed specially for immunofluorescence, with 1 ml 
medium containing 10% FCS. After culturing overnight (37°C, 5% CO2), cells were 
starved (2.2.9) for 48 hours. 
 
2.8.1.2 Cell Immunofluorescence Assay Procedure 
After an incubation of 48 hours (2.8.1.1) medium was removed and the 
immunofluorescence assay performed. Images were evaluated under a microscope 
(Olympus, Germany). 
 
Preparation of Reagents: 
• Blocking buffer - 3% bovine serum albumin (BSA) in TBST 
• Diluting buffer - 1% bovine serum albumin (BSA) in TBST 
• Phosphate buffered saline (PBS) - 0.2 g KCl, 0.2 g KH2PO4, 8.0 g NaCl, 1.44 g 
Na2HPO4·2H2O diluted with distilled water to a final volume of 1 liter, pH=7.4 
• Fixation buffer - Ice cold acetone and methanol mixture (1:1) 
• Tris buffered saline Tween-20 (TBST) - 8.0 g NaCl, 0.2 g KCl, 3 g Tris-base, 500 
μl Tween-20 diluted with distilled water to a final volume of 1 liter, pH=7.4 
• First antibody – Cytokeratin 18 (Epitomics) from rabbit, 1:200 diluted in diluting 
buffer 
• Second antibody - Goat anti-rabbit IgG labelled with Alexa Fluor® 546 dye 
(Invitrogen), 1:200 diluted in diluting buffer 
Culture 6x104 cells with 1 ml medium (10% FCS) in each well of 
an Imaging Plate FC (24 wells) 
Replace medium (10% FCS) with medium (1% FCS) 
 
Cell immunofluorescence 
Figure 11.  Procedure of preparation of cells for immunofluorescence 
Incubate over night at 37°C  
Incubate 48 hours at 37°C 
 43
• Nuclei staining buffer - Hoechst dye (Invitrogen), 1:1000 diluted in PBS 
 
Cell Immunofluorescence Assay  
1. After 48 hours (2.8.1), all wells were emptied and washed with PBS for 2 
times. 
2. 200 μl fixation buffer was added to each well. The plate was incubated for 10 
minutes on an orbit shaker at RT. 
3. Wells were emptied and then washed with PBS for 3 times. 
4. 200 μl blocking buffer was added into each well. The plate was incubated for 1 
hour on an orbit shaker at RT. 
5. The blocking buffer was removed from each well. 
6. Immediately, 200 μl first antibody was added into each well. The plate was 
incubated overnight at 4°C. 
7. Wells were emptied and then washed with PBS for 3 times. 
8. 200 μl second antibody was added into each well. The plate was  incubated 
for 1 hour at RT protected from light.  
9. Wells were emptied and then washed with PBS for 3 times protected from 
light. 
10. 200 μl nuclei staining buffer was added into each well, protected from light and 
incubated for 5 minutes on an orbit shaker at RT. 
11. Wells were emptied and then washed with PBS for 3 times. 
12. 500 μl PBS was added into each well and the plate was protected from light. 
13. Observation was done under a confocal microscope. 
 
2.8.2 Characterization of Endometrial and Endometriotic Cells by Western 
Blotting 
The CK18 and α-smooth muscle actin monoclonal antibodies were used to analyse 
the purity of the lysates from the cell lines by Western blotting assay comparable to 
the immunofluorescence analysis.  
 
2.8.2.1 Preparation of Cells for Western Blot Assay 
The procedure for preparation of endometrial and endometriotic cells for Western 
blotting assay is described below 
1. Cells were cultured with 10% FCS medium and incubated overnight at 37°C, 
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5% CO2. 
2. Medium was removed and cells washed once with 15 ml ice-cold PBS on ice. 
3. The ice-cold PBS was removed and 10 ml ice-cold PBS added on ice. 
4. Cells were scrapped and transferred to labeled and weighed 50 ml falcon 
tube. 
5. The cell culture culture flasks were rinsed with 5 ml ice cold PBS and cell 
contents transferred into appropriate 50 ml falcon tube. 
6. The falcon tube were centrifuged for 5 minutes at 1200x g at 4°C.  
7. Supernatants were discarded and the 50 ml falcon tube together with cell 
pellets was weighed.  
8. The 50 ml falcon tube containing the pellets was transferred into the liquid 
nitrogen tank for 5 minutes. 
9. The 50ml falcon tube with the cell pellet was stored at -80°C. 
 
2.8.2.2 Isolation of Proteins from Cells  
Cells stored in -80°C (2.8.2.1) were removed and proteins were isolated.  
Reagents preparation: 
• Homogenization Buffer - 7.88g Tris-HCl, 0.416 g EDTA, 1 ml of 10mM DTT, 1 ml 
of 100 mM PMSF diluted with distilled water to a final volume of 1 liter, pH=7.4 
 
Protein Isolation Procedure 
1. Stored cells were removed from -80°C (2.8.2.1) and put on ice. 
2. 0.1g of cells were resuspended in 1 ml ice-cold homogenization buffer.  
3. The mixture was put in a Potter-Elvehjem Tissue Grinder (Homogenizer). 
4. The pellet was crushed with a pestle and the mixture transferred into a 15 ml 
falcon tube. 
5. The Potter-Elvehjem Homogenizer was rinsed with 1 ml ice-cold 
homogenization buffer and the cell contents transferred into a 15 ml falcon 
tube. 
6. Centrifugation was done for 8 minutes at 3000g at 4°C. 
7. The liquid phase was collected and the pellet was discarded.  
8. The proteins in the liquid phase were quantified using the BCA method. 
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2.8.2.3 Protein Quantification  
Protein quantification was performed to ensure equivalent loading of samples on the 
gels. The proteins isolated from cells (2.8.2.2) were quantified with the Pierce 
bicinchonic acid (BCA) protein assay (Thermo Scientific, USA).  
The kit contains: 
• BCA Reagent A - 500 ml of sodium carbonate, sodium bicarbonate, bicinchonic 
acid and sodium tartrate in 0.1M NaOH.  
• BCA Reagent B - 25 ml of 4% cupric sulfate 
• BCA Working Reagent - 50 parts of BCA Reagent A with 1 part of BCA Reagent B 
(50:1). 
• Albumin Standard Ampules - 2 mg/ml in 1 ml ampules, containing bovine serum 
albumin (BSA) at 2 mg/ml in 0.9% saline and 0.05% sodium azide  
 
Preparation of reagents: 
•  Diluted Albumin (BSA) Standards - The BSA standards were prepared in BCA 
working reagent to get serial dilutions (25-2,000 μg/ml). The BCA working Reagent 
alone was used as a blank.  
Assay procedure.  
1. Reagents and samples were prepared as described above. 
2. 25 μl standards or sample were added to each well of 96-well plate. 
3. 200 μl working reagent was added to each well. The plate was mixed 
thoroughly on a shaker for 30 seconds and incubated for 30 minutes at 37°C. 
4. The OD values were measured at 562 nm on a microplate reader.  
5. Aliquots of quantified samples were stored at -80 °C until use in Western blot 
experiments. 
 
2.8.2.4 Preparation of Gels 
10% gels were prepared for separation.  
Preparation of reagents: 
• Separating buffer - 1.5 M Tris Base, 0.4% SDS, diluted with double distilled water 
to a final volume of 500 ml, the pH was adjusted to 8.8 with HCl and stored at 4 °C 
until use.  
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• Stacking buffer - 1 M Tris Base, 0.4% SDS, diluted with double distilled water to a 
final volume of 200 ml, the pH was adjusted to 6.8 with HCl and stored at 4 °C until 
use.  
• Ammonium persulphate (APS) - 10% APS in double distilled water, aliquoted and 
stored at -20°C until use. 
•TEMED (Roth, Germany) 
• Acrylamide/ Bisacrylamide solution (AppliChem, Germany) 
 
Assay Procedure (one gel) 
All reagents were brought to room temperature before use. The gel cast was 
assembled with 1.5 mm spacers and tested with double distilled water for leaks. First 
the separation gel (10%) was prepared with 3.1 ml separation buffer, 4.1 ml 
acrylamide/bisacrylamide solution and 8.5 μl TEMED in 5.2 ml double distilled water. 
85 μl ammonium persulphate was added to start the crosslinking reaction. This 
solution was immediately transferred into the gel cast with a plastic Pasteur pipette 
and overlaid with isobutanol, to stop interference of air with the crosslinking reaction. 
The remaining solution was used to confirm polymerization, which takes 
approximately 20 minutes. The isobutanol was poured off slowly, the top of the gel 
rinsed with double distilled water and dried with a blotting paper.  
The stacking gel (5%) was prepared with 1.25 ml stacking buffer, 825 μl 
acrylamide/bisacrylamide solution and 5 μl TEMED in 2.85 ml double distilled water. 
50 μl ammonium persulphate was added to start the crosslinking reaction. This 
solution was immediately overlaid on the separating gel and the gel comb inserted 
carefully to avoid bubbles. The remaining solution was used to confirm 
polymerization, which takes approximately 20 minutes. 
 
2.8.2.5 SDS-polyacrylamide Gel Electrophoresis and Protein Transfer  
 
Preparation of reagents: 
• 5x SDS running buffer - 0.125 M Tris Base, 1.25 M Glycine, 10% SDS, diluted 
with double distilled water to a final volume of 2000 ml and stored at 4 °C until use. 
• Blotting buffer - 1.0 M Tris Base, 1.25 M Glycine, 1000 ml methanol, diluted with 
double distilled water to a final volume of 2000 ml. The pH was adjusted to 8.1-8.4 
and the buffer stored at 4 °C until use.  
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• 4x Sample buffer - 12.5ml stacking buffer, 5% SDS, 40% Glycerin, 0.004% 
bromophenol blue, diluted with double distilled water to a final volume of 50 ml. The 
pH was adjusted to 6.8 with HCl and the buffer stored at room temperature until use.  
• Human Uterus Protein Medley (Clontech, USA) - 10 mg/ml protein solution in 
Laemmli buffer. 
• Spectra Multicolour Broad Range Protein Ladder (Thermo Scientific, USA). 
 
Assay Procedure 
All reagents were brought to room temperature before use. The gel assembly was 
taken out of the casting apparatus and put into the gel tank. 5x SDS running buffer 
was diluted to 1x and then poured into the tank so that the buffer level was above the 
top of the gel (approximately 900 ml). The comb was removed and the wells rinsed 
with the running buffer with the gel still in the gel tank. Aliquots of the cell lysates 
(2.8.2.3) were removed from -80°C, appropriate volumes were transferred to 
eppendorf tubes, sample buffer was added at 1/6th of the volume of the lysate and 
then boiled (100°C) for 5 minutes. 30 μg of the lysates were loaded into the wells 
using gel loading tips, run against a protein standard (Spectra Multicolour Broad 
Range Protein Ladder) and a positive control (Human Uterus Protein Medley). Gels 
were electrophoresed at 80V for two hours. 
A PVDF membrane (Millipore, USA) was cut to the exact size of the gel and soaked 
in methanol (ten seconds), double distilled water (two minutes) followed by full 
immersion in blotting buffer. Blotting paper and sponges were also soaked in blotting 
buffer. The gels were removed from the electrophoresis tank and carefully removed 
from the glass plates. The gels were sandwiched in a transfer cassette (Fig. 12). The 
transfer cassette was loaded into the gel tank and an ice pack was added before 
adding blotting buffer.  Electrophoresis was performed at 100V for 90 minutes. 
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White side of transfer cassette 
Sponge 
Blotting paper 
PVDF membrane 
Gel 
Blotting paper 
Sponge 
Black side of cassette 
 
 
 
2.8.2.6 Immunoblotting  
Immunoblotting of the PVDF membrane was performed after protein transfer. 
Preparation of reagents: 
• Tris buffered saline Tween-20 (TBST) tablets – One tablet of TBST (Medicago, 
Sweden) diluted with double distilled water to a final volume of 500 ml.  
• Blocking buffer – 5 % Skim Milk Powder (Fluka BioChemika, Zwitzerland), in 
TBST 
• Primary antibodies – Cytokeratin 18 (Epitomics), from rabbit, 1:1000 diluted in 
blocking buffer 
– α-smooth muscle actin (DAKO), from mouse, 1:500 diluted in blocking buffer 
• Secondary antibodies – Anti-rabbit Alkaline Phosphatase (Perkin Elmer, USA), 
1:2000 diluted in blocking buffer for the Cytokeratin 18 antibody 
– Anti-mouse Alkaline Phosphatase (Perkin Elmer, USA), 1:20000 diluted in blocking 
buffer for α-smooth muscle actin 
• Western LightningTM CDP-Star Chemiluminescence Reagent (Perkin Elmer, 
USA). 
 
Immunoblotting assay procedure 
Following protein transfer, the membrane was blocked with blocking buffer  (5 ml) in 
a 50 ml falcon tube for one hour gently on a roller. After discarding the blocking 
buffer, the membrane was incubated with Cytokeratin 18 or α-smooth muscle actin 
primary antibody diluted in blocking buffer overnight at 4 °C on a roller. Thereafter, 
membranes were washed 3x 5 min in TBST solution followed by incubation with 
Figure 12. Scheme for assembly of SDS-PAGE transfer cassette 
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either Anti-rabbit Alkaline Phosphatase or Anti-mouse Alkaline Phosphatase 
secondary antibody for Cytokeratin 18 or α-smooth muscle actin primary antibody, 
respectively. Incubation was done gently for one hour at room temperature on a roller 
protected from light. Membranes were washed 4x 10 min and then detection was 
done in the dark by addition of Western LightningTM CDP-Star Chemiluminescence 
Reagent to the membranes for two minutes before the membrane was sandwiched 
between Saran wrap (Dow Company, Germany). The membrane was placed into an 
X-ray cassette and an X-ray film (Fuji) was placed on the membrane. The X-ray 
cassette was closed and then exposure done for various times. The X-ray film was 
developed in a developer (AGFA Healthcare, Belgium) until a good signal was 
observed. The film was rinsed once with distilled water and fixed in a rapid fixer 
(AGFA Healthcare, Belgium) for 5 minutes. Then the film was rinsed in running tap 
water and allowed to dry. 
 
2.9 Characterization of Endometrial and Endometriotic Tissues by 
Immunohistochemistry 
Endometrial and endometriotic glands were examined in vivo by 
immunohistochemistry for cytokeratin 18 (CK 18) and Mucin-1 (MUC1) proteins.  
 
2.9.1 Patient Recruitment 
The study included women undergoing laparoscopy who had provided a written 
informed consent under the study protocol 95/09 approved by the Ethics Committee 
of the Medical Faculty of the Justus-Liebig-University, Giessen, Germany. 
Endometrial and ovarian tissues were obtained by laparoscopy from endometriotic 
patients. Endometriosis was staged according to the revised American Fertility 
Society System (rAFS). Also, tissues were obtained from patients who did not show 
endometriosis after laparoscopy and were used as control. 
 
2.9.2 Preparation of Tissue Samples 
Immediately after collecting the tissue samples, they were fixed in Bouins solution 
and embedded in paraffin. The tissues were cut to a thickness of 5 µm. 
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2.9.3 Immunohistochemistry of Endometrial and Ovary Tissues 
1. Slides were deparaffined and rehydrated with consecutive simmering in Neoclear 
and ethanol in the following way: 
• Three times for 20 min in Neoclear (Baker, Netherlands) 
• Two times for 5 min in ethanol 100% (Baker, Netherlands) 
• Two times for 5 min in ethanol 96% (Baker, Netherlands) 
• Two times for 5 min in ethanol 70% (Baker, Netherlands) 
2. Slides were washed for 5 min in distilled water on a shaker. 
3. Unmasking of the antigens on the sections was done by heating the slides in 
gourmetgarer (Braun, Germany) with citrate buffer, pH 6.0 at 100 °C for 20 
minutes. 
4. Slides were removed from citrate buffer and allowed to cool at room temperature 
for 20 minutes. 
5. Slides were washed three times for 5 min in PBS on a shaker. 
6. To inhibit unspecific protein binding, the slides were incubated with 3% H2O2 in 
methanol at room temperature for 30 minutes. 
7. Slides were washed three times for 5 min in PBS on a shaker and then put in 
1.5% BSA (Roth, USA) for 20 min on a shaker. 
8. Primary CK 18 (Epitomics; USA) and MUC1 (Epitomics, USA) antibodies were 
diluted in antibody diluent (Dako, USA) at a dilution of 1:300 and 1:200, 
respectively and then applied to the tissue sections in a moist chamber and 
incubated overnight at 4 °C. 
9. Slides were washed three times for 5 min in PBS on a shaker. 
10. Secondary antibody (Dako, USA) was added until it covered the tissue section 
and slides incubated at room temperature for 30 minutes. 
11. Slides were washed three times for 5 min in PBS on a shaker. 
12. Slides were incubated with the substrate chromogen system solution DAB (Dako, 
USA) and microscopically controled. 
13. Slides were washed three times for 5 min in distilled water on a shaker. 
14. The tissue sections were counterstained with haematoxylin (Waldeck, USA) for 45 
seconds. 
15. The haematoxylin was rinsed off by putting the slides in running tap water for at 
least 10 minutes. 
16. The slides were mounted with Eukitt quick-hardening mounting medium (Fluka 
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Analytical, Germany). 
 
2.10 Proximity Ligation Assay (PLA) 
The influence of TGF-β1 or TGF-β2 on interaction of TβRI, TβRII and TβRIII 
receptors on endometrial and endometriotic cells in vitro (Signalosome analysis) was 
investigated by use of DuolinkR In Situ kit (Olink Bioscience, Sweden).  
The kit contains: 
• PLA probe Anti-Goat PLUS (5x) - Donkey anti-goat secondary antibody 
conjugated to oligonucleotide PLUS enough for 30 reactions. Each reaction is based 
on 40 μl of the total reaction mixture covering 1cm2. 
• PLA probe Anti-Rabbit MINUS (5x) - Donkey anti-rabbit secondary antibody 
conjugated to oligonucleotide MINUS (30 reactions). Each reaction is based on 40 μl 
of the total reaction mixture covering 1cm2. 
• Blocking solution (4 ml) - for 30 reactions.  
• Antibody Diluent (2.5 ml) - For dilution of PLA probes and primary antibodies (30 
reactions). 
• Ligation (5x) - Contains oligonucleotides that hybridize to the PLA probes 
 (30 reactions). 
• Ligase (1 unit/μl) - Enough for 30 reactions.  
• Amplification Red (5x) - Contains all components needed for Rolling Circle 
Amplification (RCA). It also contains oligonucleotide probes labeled with a 
fluorophore that hybridizes to the RCA product (30 reactions). 
• Polymerase (10 units/μl) - Enough for 30 reactions. 
• Wash buffer A - Contains 3 pouches. For washes after the ligation, incubation with 
primary antibodies and PLA probes. 
• Wash buffer B - Contains 1 pouch. For washes after incubation with the 
amplification reagents. 
• Mounting Medium with DAPI - For preserving fluorescence signals.  
 
2.10.1 Preparation of cells for PLA  
Cells were cultured in 8-well chamber slides, treated with TGF-βs, fixed and then 
permeabilized as described (Fig. 13).   
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Reagent Preparation 
•  Phosphate buffered saline (PBS) - 0.2 g KCl, 0.2 g KH2PO4, 8.0 g NaCl, 1.44 g 
Na2HPO4·2H2O diluted with distilled water to a final volume of 1 liter, pH=7.4 
• Tris buffered saline (TBS)  (1x) - 3.025 g Tris Base, 4.38 g  NaCl, diluted with 
distilled water to a final volume of 500 ml, pH=7.6 
• 10% Neutral Buffered Formalin - 2 g NaH2POH2O, 3.25g NaHPO4  50ml 
Formaldehyde (37-40%) diluted with double distilled water to a final volume of 500ml, 
pH=6.8 
• 10% Triton X-100 -Triton X-100 stock diluted with double distilled  water (1:10) 
• 0.25% Triton X-100 - 10 % Triton X-100 in TBS (1:40) 
 
 
 
 
 
 
 
Culture 2x104 cells with 0.1ml medium (10% FCS) in 8-well 
chamber slide 
Replace medium (10% FCS) with medium (1% FCS) 
 Stimulate cells with TGF-β1  
Stimulate cells 
with TGF-β2  
Incubate 8 hours at 37 °C 
Incubate 30 min at 37 °C 
Add PBS as 
negative control  
Incubate overnight at 37 °C 
Empty and wash all wells with PBS  
Remove the chambers, cycle cells with hydrophobic barrier pen 
Fix the cells with 50 μl of 10% Neutral Buffered Formalin to each well 
 Incubate 30 min at RT  
Permeabilize the cells with 0.25% Triton X-100 in a Coplin jar 
Proximity Ligation Assay 
Figure 13. Scheme for preparation of cells for PLA 
 Incubate 10 min at RT  
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2.10.2 Proximity Ligation Assay procedure 
The fixed and permeabilized cells as described in 2.9.1 were used for PLA. 
 
Preparation of Reagents 
• PLA probe Anti-Goat PLUS (5x) - After vortexing, it was diluted 1:5 in antibody 
diluent and vortexed again. Equal volumes of diluted PLA probe Anti-Goat PLUS and 
PLA probe Anti-Rabbit MINUS were mixed and vortexed immediately before addition 
to the slide. 
• PLA probe Anti-Rabbit MINUS (5x) - After vortexing, it was diluted 1:5 in antibody 
diluent and vortexed again. Equal volumes of diluted PLA probe Anti-Rabbit MINUS 
and PLA probe Anti-Goat PLUS were mixed and vortexed immediately before 
addition to the slide. 
• Blocking solution (4 ml) - Vortexed before use. Ready-to-use.  
• Antibody Diluent (2.5 ml) - Vortexed before use. Ready-to-use. 
• Ligation (5x) - Thawed at room temperature and diluted 1:5 in double distilled 
water immediately before use. 
• Ligase (1 unit/μl) - The ligase was kept in a freezing block (-20°C) when diluted 
1:40 in the ligation mixture prepared above. It was thoroughly mixed and then added 
to the slide. 
• Amplification Red (5x) - Thawed at room temperature and diluted 1:5 in double 
distilled water immediately before use. 
• Polymerase (10 units/μl) - The polymerase was kept in a freezing block (-20°C) 
when diluted 1:80 in the amplification mixture prepared above. It was thoroughly 
mixed and then added to the slide. 
• Wash buffer A- To prepare 1x buffer, the content of 1 pouch was dissolved in 
double distilled water to a final volume of 1L. 
• Wash buffer B - To prepare 1x buffer, the content of 1 pouch was dissolved in 
double distilled water to a final volume of 1L. 
•  Mounting Medium with DAPI - It was vortexed before use. Ready-to-use.  
• Primary antibodies  
          • TGFβ RI antibody (Santa Cruz, USA) from goat, 1:200 diluted in    
     Duolink antibody diluent. Equal volumes of diluted TGFβRI and TGFβ 
 54
     RII antibodies were mixed and vortexed immediately before addition to  
     the sample. 
          • TGFβ RII antibody (Abcam, UK) from rabbit, 1:350 diluted in  
     Duolink antibody diluent. Equal volumes of diluted TGFβRII and TGFβ  
     RI or TGFβRIII antibodies were mixed and vortexed immediately before  
     addition to the sample. 
          •  TGFβRIII antibody (R&D Systems, USA) from goat, 1:200 diluted  
     in Duolink antibody diluent. Equal volumes of diluted TGFβRIII and  
    TGFβRII antibodies were mixed and vortexed immediately before  
     addition to the sample. 
 
PLA Assay Procedure 
1. Cells were washed with PBS for 3 x 5 minutes in a Coplin jar with agitation at 
RT. 
2. One drop of Duolink II blocking solution was added to each well and the slides 
incubated for 1 hour at 37°C. 
3. 40 μl of the antibody pair was added into each well. In some wells, the primary 
antibody was omitted and instead 40 μl antibody diluent was added (Control). 
The slides were incubated over night at 4°C. 
4. The slides were washed with 1x wash buffer A for 3x5 minutes in a Coplin jar 
with agitation at RT.  
5. 40 μl of mixed and diluted PLA probes (MINUS+PLUS) were added into each 
well followed by an incubation for 1 hour at 37°C.  
6. The slides were washed with 1x wash buffer A for 2x5 minutes in a Coplin jar 
with agitation at RT. 
7. 40 μl of ligation-ligase solution was added to each well. The slides were 
incubated for 30 minutes at 37°C. 
8. The slides were washed with 1x wash buffer A for 2x2 minutes in a Coplin jar 
with agitation at RT. 
9. 40 μl of Amplification-Polymerase solution was added to each well, protected 
from light, incubated for 100 minutes at 37°C.  
10. The slides were washed with 1x wash buffer B for 2x10 minutes in a Coplin jar 
with agitation at RT and protected from light. 
11. The slides were dipped in 0.1x wash buffer B for 1 minute in a Coplin jar.  
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12.  40 μl mounting medium with DAPI was added on the cover slip and gently 
placed over the slide.  
13.  After 15 minutes, the samples were analyzed under the olympus fluorescence 
microscope.  
14. The signals on the images were counted to obtain quantification of the signals. 
 
2.11 Statistical Methods 
Statistical analysis was performed to analyse experimental data. Each experiment 
was done at least three times in duplicate. The experimental data are expressed as 
means+SEM. The significance of the data was analysed by use of Instat Graphpad® 
statistics software and we performed the Kruskal-Wallis test which is a non-
parametric test for all experimental data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56
3 Results 
 
3.1 Characterization of Endometrial and Endometriotic Tissues and Cells 
3.1.1 Characterization of Endometrial and Endometriotic Cells 
Endometrial and endometriotic cells were characterised by immunofluorescence and 
Western blotting with cytokeratin 18 and α-smooth muscle actin monoclonal 
antibodies to assess their purity. Cytokeratin 18 is a member of intermediate filament 
proteins that are expressed preferentially as pairs mainly in epithelial tissue (Pekny 
and Lane, 2007). Cytokeratins are critical in differentiation, tissue specialization and 
function to maintain the overall structure and integrity of epithelial cells. In contrast,  
stromal cells were characterised by antibodies against α-smooth muscle actin which 
is expressed mainly in smooth muscle cells, myofibroblasts and myoepithelial cells 
(Ogawa, 2003).  
Cells were grown overnight and then fixed with ice-cold acetone/methanol (1:1). A 
high affinity cytokeratin 18 antibody was used as primary antibody. A goat anti-rabbit 
IgG labelled with Alexa Fluor® 546 dye was used as secondary antibody; nuclei were 
counterstained with Hoechst dye (Fig. 14).  
  
 
    
Figure 14. The epithelial HES (A) and 12ZVK (B) cells which represent endometrial and endometriotic 
epithelial cells, respectively, were strongly positive for cytokeratin 18. No staining for cytokeratin 18 
was observed in T-HESC (C) and 22B (D) cells which represent endometrial and endometriotic 
stromal cells, respectively.  
 
 B (12ZVK)  A (HES) 
   C (T-HESC)   D (22B) 
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In addition to the immunofluorescence, the CK 18  and anti-α-smooth muscle actin 
antibodies were further used to analyse the lysates from the cell lines by Western 
blotting (Fig. 15). 
 
 
 
     Positive        49Z       12ZVK        Primary        22B         T-H      St-T1b        HUF         HES 
     Control                                          Cells 
 
 
 
 
        49Z        12ZVk          Primary             22B              T-H           St-T1b             HUF               HES 
                                           Cells 
 
Figure 15. Cytokeratin 18 (A) and α-smooth muscle actin (B) expression in endometrial and 
endometriotic cell lysates. Cytokeratin 18 expression (42kDa) was found in HES cells and 12ZVK cells 
which represent endometrial and endometriotic epithelial cells, respectively, but not in T- HESC (T-H) 
cells and 22B cells, which represent endometrial and endometriotic stromal cells. In addition, there 
was no cytokeratin 18 expression in primary endometrial stromal cells. Alpha-smooth muscle actin 
(45kDa) was expressed in endometrial and endometriotic cell lysates of T- HESC (T-H) cells, 22B cells 
and primary endometrial stromal cells but not in HES or 12ZVK cells. 
 
3.1.2 Characterization of Endometrial and Endometriotic Tissues 
Endometrial and endometriotic glands were examined by immunohistochemistry to 
assess their characteristics. Endometrial biopsies were obtained from patients with or 
without endometriosis and then assessed for expression of cytokeratin 18 (CK 18) 
and Mucin-1 (MUC1). MUC1 is a member of the mucin family, is normally expressed 
on polarised epithelial cells and is also a component of glandular secretions 
(Thathiah and Carson, 2004; Hattrup and Gendler, 2008). Abnormal MUC1 
expression has been observed in over 80% of all cancers and is often associated 
with poor prognosis (Hattrup and Gendler, 2008). 
Both CK 18 and MUC1 were expressed in all endometrial glands of the endometrium. 
There were no differences observed in staining in patients with endometriosis (Fig. 
Cytokeratin 18 
α-smooth muscle actin 
A
B 
42kDa
45kDa
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16A and 16C) or without endometriosis (Fig. 16B and 16D). Further analysis of the 
expression of both proteins in the ovary was performed. In the ovaries, all 
endometriotic glands stained positive with CK 18 (Fig. 17A and 17B) as well as with 
MUC1 (Fig. 17C and 17D). 
 
 
 
Figure 16. Immunohistochemical detection of CK 18 (A, B) and MUC 1 (C, D) in the endometrium of 
patients without endometriosis (B, D) and patients with endometriosis (A, C). Magnification 200X. 
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Figure 17. Immunohistochemical detection of CK 18 (A, B) and MUC 1 (C, D) in the ovaries of 
patients without endometriosis (B, D) and patients with endometriosis (A, C). Magnification 200X. 
 
In summary, MUC 1 was expressed in all endometrial and endometriotic glands of all 
tissues. CK 18 was expressed in endometrial and endometriotic glands of 
endometrium and ovary. In addition, the surface epithelium of the ovary expressed 
CK 18. 
 
 
3.2 Influence of TGF-β1 or TGF-β2 on Cell Numbers 
In order to find out how TGF-βs affect cell numbers, we treated endometrial, 
endometriotic cell lines and primary endometrial stromal cells with TGF-β1 or TGF-β2 
(10ng/ml), respectively.  
The results showed that TGF-β1 or TGF-β2 reduced cell numbers of both 
endometrial and endometriotic cell lines and primary endometrial stromal cells      
within 72 hours (Fig. 18).  Reduction was higher in endometrial cells in comparison 
with endometriotic cells. 
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Figure 18. Quantification of cell numbers of endometrial cells (A), endometriotic cells (B) and primary 
endometrial stromal cells (C) with or without treatment with TGF-βs (10ng/ml). The quantity of 
endometrial epithelial cells (HES) was reduced by approximately 39% and that of endometrial stromal 
cells (T-HESC) was reduced by approximately 51% (A). Endometriotic epithelial cell numbers (12ZVK) 
were reduced by approximately 21% and of endometriotic stromal cells (22B) by approximately 13% 
(B). Primary endometrial stromal cell numbers were reduced by approximately 19% (C).  (**=P<0.01, 
*=P<0.05, n=9). 
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3.3 Analysis of the Smad Pathway in Endometrial and Endometriotic Cells 
The inhibitors LY364947 and SiS3 were used to investigate the role of the Smad-
dependent pathway in cell proliferation. LY364947 and SiS3 inhibitors block the 
phosphorylation of Smad2/3 by selectively inhibiting TβR1 or Smad3, respectively. 
LY364947 (5 μM) or SiS3 (2 μM) were added two hours before adding the TGF-βs 
(10ng/ml). Cells were cultured for 72 hours after stimulation with the TGF-βs. The 
appropriate negative controls were also performed. 
The results showed that TGF-β1 and TGF-β2 reduced cell numbers in all cell lines 
studied (Figs. 19-21). LY364947 was able to block completely the TGF-β-induced 
reduction in cell numbers to control levels in all cell lines studied, whereas SiS3 had 
only a partial but strongly reducing effect (70%) in blocking the TGF-β-induced 
reduction in cell numbers. 
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Figure 19. The TβR1 inhibitor LY364947 completely inhibited the TGF-β1- or TGF-β2-induced 
reduction of endometrial cell numbers of both endometrial epithelial cells, HES (A), and endometrial 
stromal cells, T-HESC (B). The Smad3 inhibitor SiS3 partially inhibited the TGF-β1- or TGF-β2-
induced reduction of endometrial cell numbers of both endometrial epithelial cells, HES (A), and 
endometrial stromal cells, T-HESC (B), by approximately 60% and 80%, respectively (*=P<0.05, n=9). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 20. The TβR1 inhibitor (LY364947) completely inhibited the TGF-β1- or TGF-β2-induced 
reduction of endometriotic cell numbers of both endometriotic epithelial cells, 12ZVK (A), and 
endometriotic stromal cells, 22B (B). The Smad3 inhibitor SiS3 partially inhibited the TGF-β1- or TGF-
β2-induced reduction of endometriotic cell numbers of both endometriotic epithelial cells, 12ZVK (A), 
and endometriotic stromal cells, 22B (B), by approximately 70% and 90%, respectively (*=P<0.05, 
n=9). 
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Figure 21. The TβR1 inhibitor (LY364947) completely inhibited the TGF-β1- or TGF-β2-induced 
reduction of cell numbers, whereas the Smad3 inhibitor SiS3 only partially inhibited the TGF-β1- or 
TGF-β2-induced reduction of cell numbers of primary endometrial stromal cells (*=P<0.05, n=9). 
These results were comparable to the results obtained with the endometrial stromal cell line, T-HESC 
(Fig. 19B). 
 
3.4 Influence of TGF-β1 or TGF-β2 on Smad3 Phosphorylation of Endometrial 
and Endometriotic Cells in vitro 
Smad3 is a member of a transcription factor family involved in mediating signaling of 
growth factors such as TGF-βs and activins. Smad3 belongs to a class of SMAD 
proteins that are activated via phosphorylation by specific receptors in response to 
ligand binding (Derynk et al., 1998). Upon TGF-β binding, Smad3 is phosphorylated 
by the TGF-β receptor then dissociates from the TGF-β receptor and interacts with 
Smad4 either in the cytoplasm or nucleus. This Smad complex  modulate the TGF-β-
induced transcription of genes (Attisano and Wrana, 2002). Smad3 is one of the 
standard proteins for studying the Smad-dependent effects of TGF-βs. 
In our experiments, endometrial, endometriotic cell lines and primary endometrial 
stromal cells were treated with or without TGF-β1 or TGF-β2 (10ng/ml) for 30 
minutes and then cell lysates were collected for the phospho-Smad3 ELISA to 
quantitate phosphorylated human Smad3. 
Treatment of cells with TGF-β1 or TGF-β2, respectively, stimulated phosphorylation 
of Smad3 in endometrial, endometriotic cell lines (Fig. 22A and B), and primary 
endometrial stromal cells (Fig. 22C). Stimulation was higher in stromal cells 
compared to epithelial cells in both endometrial and endometriotic cells. 
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Figure 22. Treatment of cells with TGF-β1 or TGF-β2, respectively, stimulated phosphorylation of 
Smad3. Smad3 phosphorylation was 2-fold higher in endometrial stromal cells, T-HESC, compared to 
endometrial epithelial cells, HES (A). In endometriotic stromal cells, 22B, 2-fold more Smad3 
phosphorylation was observed compared to endometriotic epithelial cells, 12ZVK (B). Interestingly, in 
endometrial cells more Smad3 phosphorylation occured compared to endometriotic cells. Primary 
endometrial stromal cells showed similar Smad3 phosphorylation levels compared to endometrial 
stromal cells, T-HESC (C) (**=P<0.01, *=P<0.05, n=9). 
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Analysis of the Smad3 Pathway in Endometrial and Endometriotic Cells 
The inhibitors LY364947 and SiS3 were used to investigate the role of the Smad-
dependent pathway in Smad3 phosphorylation. The inhibitors block phosphorylation 
of Smad2/3 by selectively inhibiting TβR1 and Smad3, respectively. LY364947 (5 
μM) or SiS3 (2 μM) was added two hours before adding the TGF-βs (10ng/ml). Cells 
were incubated for 30 minutes after stimulation with the TGF-βs. Then cell lysates 
were collected to quantitate the amounts of phosphorylated Smad3 by phospho-
Smad3 ELISAs. 
The results showed that treatment of cells with TGF-β1 or TGF-β2, respectively, 
resulted in Smad3 phosphorylation in all cell lines. The LY364947 and SiS3 inhibitors 
were able to block completely the TGF-β-induced Smad3 phosphorylation in all cell 
lines studied (Figs. 23-25).   
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Figure 23. Treatment of endometrial cells with TGF-β1 or TGF-β2, respectively, stimulated 
phosphorylation of Smad3. Smad3 phosphorylation was 2-fold higher in endometrial stromal cells, T-
HESC (B), compared to endometrial epithelial cells, HES (A). LY364947 and SiS3 inhibitors 
completely blocked the TGF-β-induced Smad3 phosphorylation in endometrial cells (**=P<0.01, n=6). 
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Figure 24. Treatment of endometriotic cells with TGF-β1 or TGF-β2, respectively, stimulated 
phosphorylation of Smad3. Smad3 phosphorylation was 2-fold higher in endometriotic stromal cells, 
22B (B), compared to endometriotic epithelial cells, 12ZVK (A). LY364947 and SiS3 inhibitors 
completely blocked the TGF-β-induced Smad3 phosphorylation in endometriotic cells (*=P<0.05, 
**=P<0.01, n=6). 
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Figure 25. TGF-β1 or TGF-β2, respectively, stimulated phosphorylation of Smad3 in primary 
endometrial stromal cells. Smad3 phosphorylation levels were very similar to the endometrial stromal 
cells, T-HESC (Fig. 23B). LY364947 and SiS3 inhibitors completely blocked TGF-β-induced Smad3 
phosphorylation in primary endometrial cells (**=P<0.01, n=6). 
 
In summary, endometrial cells showed higher phosphorylation levels of Smad3 
compared to endometriotic cells upon treatment with TGF-β1 or TGF-β2. Smad3 
phosphorylation in endometrial epithelial cells, HES, was 2-fold higher compared to 
endometriotic epithelial cells, 12ZVK. Similarly, Smad3 phosphorylation in 
endometrial stromal cells, T-HESC, was 2-fold higher compared to endometriotic 
stromal cells 22B. Primary endometrial stromal cells showed similar Smad3 
phosphorylation compared to endometrial stromal cells, T-HESC. LY364947 and 
SiS3 inhibitors completely blocked TGF-β-induced Smad3 phosphorylation in all cell 
lines studied. 
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3.5 Influence of TGF-β1 or TGF-β2 on Apoptosis of Endometrial and 
Endometriotic Cells in vitro 
Apoptosis is characterized by activation of an endogenous cell suicide programme 
which involves chromatin condensation, nuclear fragmentation, cell shrinkage, 
membrane blebbing and dissolution of cells into apoptotic bodies which are rapidly 
phagocytosed by neighbouring cells or resident macrophages (Ruaidhri  et al., 1998).  
In our experiments, we wanted to investigate whether or not TGF-βs have an 
apoptotic effect on human endometrial and endometriotic cells and if yes, which 
apoptotic pathways are involved.  
Endometrial, endometriotic cell lines and primary endometrial stromal cells were 
treated with or without TGF-β1 or TGF-β2 (10ng/ml), respectively, for 24 hours and 
then apoptosis experiments were carried out by use of ELISAs. Staurosporine 
(0.1μM) was included in the assay as a positive control. Staurosporine is a potent 
inhibitor of protein kinase C, most other kinases, and topoisomerase II by blocking 
transfer of phosphodiester bonds from DNA to the active site of tyrosine hence 
inducing apoptosis (Seynaeve et al., 1994). 
The apoptotic parameters investigated included quantification of phosphatidylserine 
on the outer membrane surface, of the inner mitochondrial membrane potential, and 
of Cysteinyl-asparate-specific proteases 3/7 (Caspase 3/7) proteins. The three 
parameters are important because they can be used to monitor necrosis and 
apoptosis. In apoptotic cells, phosphatidylserine which is usually located on the inner 
side of the cell membrane is translocated in apoptotic cells onto the outer surface of 
the cell membrane due to loss of cell symmetry (Sims and Wiedmer, 2001). The 
translocated phosphatidylserine can be quantified by ELISA. The inner mitochondrial 
membrane integrity is intact but once the cell undergoes apoptosis, the integrity of 
the inner mitochondrial potential is lost causing release of some ions among them 
cytochrome C which initiates caspase cascades leading to apoptosis (Kroemer et al., 
2007). 
The results showed an increase of phosphatidylserine, a decrease of the inner 
mitochondrial membrane potential and an increase of Caspase 3/7 levels upon 
treatment of cells with TGF-β1 or TGF-β2 (10ng/ml), respectively (Figs. 26-30).  
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Figure 26. Treatment with TGF-β1 or TGF-β2, respectively, induced apoptosis in endometrial 
epithelial cells, HES. There was an increase in the amount of translocated phosphatidylserine (A), a 
decrease of the mitochondrial membrane potential (B), and an increase of the amount of Caspase 3/7 
(C). Staurosporine strongly induced apoptosis in HES cells (*=P<0.05, **=P<0.01, ***=P<0.001, n=6). 
RFU; relative fluorescence units. 
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Figure 27. Treatment with TGF-β1 or TGF-β2, respectively, induced apoptosis in endometrial stromal 
cells, T-HESC. There was an increase in the amount of translocated phosphatidylserine (A), a 
decrease of the mitochondrial membrane potential (B), and an increase of the amount of Caspase 3/7 
(C). Staurosporine strongly induced apoptosis in T-HESC cells (*=P<0.05, **=P<0.01, ***=P<0.001, 
n=6). RFU; relative fluorescence units. 
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Figure 28. Treatment with TGF-β1 or TGF-β2, respectively, induced apoptosis in endometriotic 
epithelial cells, 12ZVK. There was an increase in the amount of translocated phosphatidylserine  (A), a 
decrease of the mitochondrial membrane potential (B), and an increase of the amount of Caspase 3/7 
(C). Staurosporine strongly induced apoptosis in 12ZVK cells (**=P<0.01, ***=P<0.001, n=6). RFU;  
relative fluorescence units. 
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Figure 29. Treatment with TGF-β1 or TGF-β2, respectively, induced apoptosis in endometriotic 
stromal cells, 22B. There was an increase in the amount of translocated phosphatidylserine (A), a 
decrease of the mitochondrial membrane potential (B), and an increase of the amount of Caspase 3/7 
(C). Staurosporine strongly induced apoptosis in 22B cells (**=P<0.01, ***=P<0.001, n=6). RFU;  
relative fluorescence units. 
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Figure 30. Treatment with TGF-β1 or TGF-β2, respectively, induced apoptosis in primary endometrial 
stromal cells. There was an increase in the amount of translocated phosphatidylserine (A), a decrease 
of the mitochondrial membrane potential (B), and an increase of the amount of Caspase 3/7 (C). 
Staurosporine strongly induced apoptosis in primary endometrial cells (**=P<0.01, ***=P<0.001, n=6). 
RFU;  relative fluorescence units. 
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In summary, either TGF-β1 or TGF-β2 induced apoptosis in all cell lines studied. 
There was an increase in the amount of phosphatidylserine translocated to the outer 
surface of the cells, an increase of Caspase 3/7 levels and a decrease of the inner 
mitochondrial membrane potential. There were no significant differences between 
endometrial and endometriotic cell lines. Furthermore, the apoptotic effects of      
TGF-β1 or TGF-β2 on primary endometrial stromal cells and endometrial stromal 
cells were similar.  
 
Analysis of the Smad Pathway in Apoptosis in Endometrial and Endometriotic 
Cells 
The inhibitors LY364947 and SiS3 were used to investigate the role of the Smad-
dependent pathway in apoptosis. The inhibitors block phosphorylation of Smad2/3 by 
selectively inhibiting TβR1 and Smad3 phosphorylation, respectively.  
LY364947 (5 μM) and SiS3 (2 μM) were added two hours before adding the TGF-βs 
(10ng/ml) or staurosporine (0.1 μM), respectively, for 24 hours and then apoptosis 
experiments were carried out by ELISAs. The apoptotic parameters tested included 
quantification of phosphatidylserine, the mitochondrial membrane potential and 
Caspase 3/7 levels.  
The results showed that treatment of cells with TGF-β1 or TGF-β2, respectively, 
increased phosphatidylserine on the outer surface of the cell membrane, decreased 
the inner mitochondrial membrane potential and increased Caspase 3/7 in all cells. 
LY364947 blocked TGF-β-mediated apoptosis in all cell lines completely, whereas 
SiS3 blocked TGF-β-mediated apoptosis in all cell lines only partially (Fig. 31).   
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Figure 31. Treatment of endometrial epithelial HES cells with TGF-β1 or TGF-β2, respectively, 
induced apoptosis. There was an increase in the amount of translocated phosphatidylserine (A) 
(**=P<0.01, ***=P<0.001, n=6), a decrease of the mitochondrial membrane potential (B) (*=P<0.05, 
**=P<0.01, n=6), and an increase of the amount of Caspase 3/7 (C) (*=P<0.05, **=P<0.01, 
***=P<0.001, n=6). LY364947 blocked TGF-β-mediated apoptosis in HES cells completely, whereas 
SiS3 blocked TGF-β-mediated apoptosis in cells only partially (A-C). Similar results were observed in 
the other cell lines (data not shown). RFU; relative fluorescence units. 
 
3.6 Influence of TGF-β1 or TGF-β2 on Plasminogen Activator Inhibitor-1 
Secretion by Endometrial and Endometriotic Cells in vitro 
Plasminogen Activator Inhibitor-1 (PAI-1) belongs to the serine protease inhibitor 
family (SERPIN) and is a modifier of pathways that impact proliferative/migratory 
events (Czekay et al., 2003), PAI-1 is one of the gold standards for studying the 
effects of TGF-βs on gene expression. Moreover, PAI-1 disrupts integrin-containing 
adhesions and actin stress fibers which might result in apoptosis or reduced cell 
numbers (Czekay et al., 2003). 
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3.6.1 Analysis of TGF-β-induced PAI-1 Secretion by Endometrial and 
Endometriotic Cells 
To investigate the effects of TGF-βs on PAI-1 secretion, endometrial and 
endometriotic cells were treated with 10ng/ml of TGF-β1 or TGF-β2, respectively. 
After 48 hours, supernatants were collected to quantitate PAI-1. 
PAI-1 secretion was increased significantly by TGF-β1 or TGF-β2, approximately 40-
fold in endometrial epithelial cells (HES), 5-fold in endometriotic epithelial cells 
(12ZVK), 3-fold in stromal cells (T-HESC, primary endometrial stromal cells, and 
22B), compared to the controls (Figs. 32-34).  
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Quantification of PAI-1 secretion by endometrial cells with or without treatment with      
TGF-βs. HES cells secreted only negligible amounts of PAI-1, but secretion was slightly increased 
upon treatment with TGF-βs. Endometrial stromal cells (T-HESC) secreted 10-fold more PAI-1 
compared to endometrial epithelial cells (HES) stimulated by TGF-β1 or TGF-β2 (10ng/ml), 
respectively (*=P<0.05, n=6). 
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Figure 33. Quantification of PAI-1 secretion by endometriotic cells with or without treatment with    
TGF-βs. Both endometriotic epithelial cells (12ZVK) and endometriotic stromal cells (22B) secreted 
more PAI-1 upon TGF-β1 or TGF-β2 (10ng/ml) treatment, respectively (*=P<0.05, **=P<0.01, n=6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Quantification of PAI-1 secretion by primary endometrial stromal cells with or without   
TGF-βs. The primary endometrial stromal cells secreted more PAI-1 upon TGF-β1 or TGF-β2 
(10ng/ml) treatment, respectively (*=P<0.05, n=6). 
 
In summary, endometriotic epithelial cells 12ZVK secreted approximately 200-fold 
more PAI-1 compared to endometrial epithelial cells HES. Endometriotic stromal cells 
22B secreted 4-fold more PAI-1 compared to endometrial stromal cells T-HESC. 
Furthermore PAI-1 secretion by primary endometrial stromal cells was nearly similar 
to secretion levels of endometrial stromal cells T-HESC.  
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3.6.2 Analysis of the Smad Pathway in PAI-1 Secretion in Endometrial and 
Endometriotic Cells 
The inhibitors LY364947 and SiS3 were used to investigate the role of the Smad-
dependent pathway in PAI-1 secretion. The inhibitors block phosphorylation of 
Smad2/3 by selectively inhibiting TβR1 and Smad3, respectively. LY364947 (5 μM) 
and SiS3 (2 μM) were added two hours before adding the TGF-βs (10ng/ml). Cells 
were cultured for 48 hours after stimulation with the TGF-βs. Then supernatants were 
collected for quantification of PAI-1 secretion by PAI-1 ELISA. 
The results showed that TGF-β1 and TGF-β2 both increased PAI-1 secretion in all 
cell lines studied. LY364947 blocked TGF-β-mediated PAI-1 secretion in cells 
completely to control levels, whereas SiS3 blocked TGF-β-mediated PAI-1 secretion 
in all cells only partially (Fig. 35). 
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Figure 35. Treatment of cells with TGF-β1 or TGF-β2 (10ng/ml), respectively, induced PAI-1 secretion 
in endometrial epithelial cells, HES (A), and endometrial stromal cells, T-HESC (B). LY364947 
blocked TGF-β-induced PAI-1 secretion of all cells completely to control levels while SiS3 blocked 
TGF-β-induced PAI-1 secretion of cells in a range of 40-70%. Similar results were observed with the 
other cell lines (data not shown). 
 
3.6.3 Analysis of the BMP Pathway in PAI-1 Secretion  
The BMP inhibitor LDN-193189 was used to study the role of the BMP pathway in 
PAI-1 secretion. The BMP inhibitor selectively inhibits the BMP type 1 receptors 
ALK2, ALK3 and ALK 6 and thus blocks BMP-mediated phosphorylation of 
Smad1/5/8. 
The BMP inhibitor (5μM) was added two hours before adding the TGF-βs (10ng/ml). 
Cells were cultured for 48 hours after stimulation with the TGF-βs. Then supernatants 
were collected for quantification of PAI-1 secretion.  
The results showed that TGF-β1 or TGF-β2, respectively, increased PAI-1 secretion 
in all cell lines studied. The BMP inhibitor demonstrated a complete decrease (100%) 
of TGF-β1 or TGF-β2 induced-PAI-1 secretion in all cell lines studied (Figs. 36-38). 
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Figure 36. Treatment of endometrial cells HES or T-HESC with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, induced PAI-1 secretion. T-HESC secreted more PAI-1 compared to endometrial 
epithelial cells HES. The BMP inhibitor blocked TGF-β-induced PAI-1 secretion in both cell lines to 
control levels (***=P<0.001, n=6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Treatment of endometriotic cells 12ZVK or 22B with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, induced PAI-1 secretion. 22B secreted more PAI-1 compared to endometriotic epithelial 
cells 12ZVK. The BMP inhibitor blocked TGF-β-induced PAI-1 secretion in both cell lines to control 
levels (**=P<0.01, ***=P<0.001, n=6). 
 
 
 
 
 
 
 
 
 
 
PA
I-1
 (n
g/
m
l/ 
50
00
00
 c
el
ls
)
Ct
rl
TG
F-
ß1
BM
P 
inh
.
TG
F-
ß1
+B
MP
 in
h.
TG
F-
ß2
TG
F-
ß2
+B
MP
 in
h.
0
500
1000
1500
**
**
***
***
12ZVK
PA
I-1
( n
g/
m
l/ 
50
00
00
 c
el
ls
)
Ct
rl
TG
F-
ß1
BM
P 
inh
.
TG
F-
ß1
+B
MP
 in
h.
TG
F-
ß2
TG
F-
ß2
+B
MP
 in
h.
0
1000
2000
3000
4000
***
***
***
***
22B
Ct
rl
TG
F-ß
1
BM
P 
inh
.
TG
F-
ß1
+B
MP
 in
h.
TG
F-ß
2
TG
F-
ß2
+B
MP
 in
h.
PA
I-1
 (n
g/
m
l/ 
50
00
00
 c
el
ls
)
Ct
rl
TG
F-ß
1
BM
P 
inh
.
TG
F-
ß1
+B
MP
 in
h.
TG
F-ß
2
TG
F-
ß2
+B
MP
 in
h.
 83
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Treatment of primary endometrial stromal cells with TGF-β1 or TGF-β2, (10ng/ml) 
respectively, induced PAI-1 secretion. The BMP inhibitor blocked TGF-β-induced PAI-1 secretion of 
primary endometrial cells to control levels (**=P<0.01, ***=P<0.001, n=6). 
 
3.6.4 Analysis of BMP Receptors in PAI-1 Secretion  
Activin Receptor-Like Kinase (ALK), namely ALK-2, ALK-3 and ALK-6, inhibitors were 
used separately to study the specific BMP receptor involved in the complete 
decrease of TGF-β1 or TGF-β2 induced-PAI-1 secretion in cells as shown by the 
BMP inhibitor LDN-193189 in section 3.6.3. 
The ALK-2 (10μM), ALK-3 (4μM), ALK-6 (6μM) inhibitors and IgG1 (2μM) were 
added two hours before adding the TGF-βs (10ng/ml). Cells were cultured for 48 
hours after stimulation with the TGF-βs. Then supernatants were collected for 
quantification of PAI-1 secretion.  
The results showed that TGF-β1 or TGF-β2 increased PAI-1 secretion of all cell lines 
studied. The ALK-2 inhibitor demonstrated a complete decrease (100%) of TGF-β1 
or TGF-β2 induced-PAI-1 secretion in all cell lines, whereas the ALK-3 and ALK-6 
inhibitors demonstrated only a partial effect of 40% and 25%, respectively. The IgG1 
(control) had no affect on TGF-β1 or TGF-β2 induced-PAI-1 secretion (Figs. 39-41). 
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Figure 39. Treatment of endometriotic cells (12ZVK) with TGF-β1 or TGF-β2 (10ng/ml), respectively, 
induced PAI-1 secretion. The ALK-2 inhibitor blocked TGF-β-induced PAI-1 secretion completely to 
control levels, whereas IgG1 had no effect on TGF-β-induced PAI-1 secretion (**=P<0.01, n=6). 
Similar results were observed in the other cell lines (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Treatment of endometriotic cells (12ZVK) with TGF-β1 or TGF-β2 (10ng/ml), respectively, 
induced PAI-1 secretion. The ALK-3 inhibitor blocked TGF-β-induced PAI-1 secretion by 40%, 
whereas IgG1 had no effect on TGF-β-induced PAI-1 secretion (*=P<0.05, **=P<0.01, n=6). Similar 
results were observed in the other cell lines (data not shown). 
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Figure 41. Treatment of endometriotic cells (12ZVK) with TGF-β1 or TGF-β2 (10ng/ml), respectively, 
induced PAI-1 secretion. The ALK-6 inhibitor blocked TGF-β-induced PAI-1 secretion by 25%, 
whereas IgG1 had no effect on TGF-β-induced PAI-1 secretion (**=P<0.05, **=P<0.01, n=6). Similar 
results were observed in the other cell lines (data not shown). 
 
3.7 Influence of TGF-β1 or TGF-β2 on Inhibin B Secretion by Endometrial and 
Endometriotic Cells in vitro 
Inhibin B belongs to the TGF-β superfamily regulates reproduction. Recent studies 
have shown that inhibins might be involved in tumour suppression (Gail et al., 2001). 
Inhibin B secretion is one possible marker for the functionality of the BMP pathway. 
Thus, by treating endometrial or endometriotic cells with TGF-β1 or TGF-β2, it might 
be possible to elucidate whether TGF-βs might also use the BMP pathway-
dependent Smad1/5/8.  
To investigate the effects of TGF-βs on inhibin B secretion, endometrial and 
endometriotic cells were treated with TGF-β1 or TGF-β2 (10 ng/ml), respectively, for 
48 hours and supernatants were collected for the inhibin B ELISA.  
The results showed that TGF-β1 or TGF-β2 reduced inhibin B secretion of HES cells 
and primary endometrial stromal cells while inhibin B secretion was not affected by 
TGF-β1 or TGF-β2 in the other cell lines studied (Figs. 42-44). 
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Figure 42. Treatment of endometrial epithelial cells (HES) with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, reduced inhibin B secretion compared to control. There were no effects on inhibin B 
levels in T-HESC cells (*=P<0.05, **=P<0.01 n=6). 
 
 
 
 
 
 
 
 
 
 
Figure 43. Treatment of endometriotic cells (12ZVK and 22B) with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, did not show any effect on inhibin B secretion. 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Treatment of primary endometrial stromal cells with TGF-β1 or TGF-β2 (10ng/ml), 
respectively reduced inhibin B secretion compared to the control (*=P<0.05, n=6). 
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3.8 Influence of TGF-β1 or TGF-β2 on TβRIII Expression of Endometrial and 
Endometriotic Cells in vitro 
High affinity binding of TGF-β2 to Transforming growth factor beta receptor II (TβRII) 
is best via TβRIII (Lopez et al., 1993). However, TGF-β1 as well as TGF-β3 also bind 
to TβRIII. 
In our experiments, 24-well plates were coated with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, and incubated for 48 hours. The cells were fixed with ice-cold 4% 
paraformaldehyde (PFA). A high affinity TβRIII antibody (R&D) was used as a 
primary antibody. An anti-goat peroxidase (DAKO) was used as a secondary 
antibody. TMB substrate (Calbiochem, Germany) was added followed by addition of 
0.18N H2SO4 to stop the reaction. Absorbance was read at 450nm. 
Treatment of cells with TGF-β1 or TGF-β2 increased expression of TβRIII on stromal 
cells whereas epithelial cells showed little or no increase (Figs. 45-47). 
 
 
 
 
 
 
 
 
 
 
Figure 45. Treatment of endometrial cells with TGF-β1 or TGF-β2 (10ng/ml), respectively, increased 
expression of TβRIII only on T-HESC cells with no effect on endometrial epithelial cells HES 
(*=P<0.05, n=6). 
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Figure 46. Treatment of endometriotic cells with TGF-β1 or TGF-β2 (10ng/ml), respectively, increased 
expression of TβRIII only on 22B cells with no effect on endometriotic epithelial cells 12ZVK 
(*=P<0.05, n=6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Treatment of primary endometrial stromal cells with TGF-β1 or TGF-β2 (10ng/ml) 
increased expression of TβRIII on the cells (*=P<0.05, n=6). The TβRIII expression was similar to the 
endometrial stromal cell line T-HESC (Fig. 45).   
 
3.9 Influence of TGF-β1 or TGF-β2 on Secretion of TGF-β2 by Endometrial and 
Endometriotic Cells in vitro 
To investigate the influence of TGF-β1 or TGF-β2 on secretion of TGF-β2 by 
endometrial and endometriotic cells, we quantitated TGF-β2 secretion by cells.  
The endometrial and endometriotic cells were treated with TGF-β1 or TGF-β2 
(10ng/ml), respectively. Then cell supernatants were collected after 48 hours upon 
TGF-β1 or TGF-β2 treatment to quantitate TGF-β1 or TGF-β2. 
Treatment of cells with TGF-β1 or TGF-β2 increased secretion of TGF-β2 in         
TGF-β1-treated cells. No effect on TGF-β2 levels was observed in controls and TGF-
β2-treated cells (Figs. 48-50). 
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Figure 48. Treatment of endometrial cells (HES and T-HESC) with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, increased secretion of TGF-β2 in TGF-β1-treated cells. Endometrial stromal cells, T-
HESC, secreted more TGF-β2 compared to endometrial epithelial cells, HES. No effect on TGF-β2 
levels was observed in controls and TGF-β2-treated endometrial cells (*=P<0.05, **=P<0.01, n=6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Treatment of endometriotic cells (12ZVK and 22B) with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, increased secretion of TGF-β2 in TGF-β1-treated cells. Endometriotic stromal cells, 22B, 
secreted more TGF-β2 compared to endometriotic epithelial cells, 12ZVK. No effect on TGF-β2 levels 
was observed in controls and TGF-β2-treated cells in endometriotic cells (*=P<0.05, **=P<0.01, n=6). 
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Figure 50. Treatment of primary endometrial stromal cells with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, increased secretion of TGF-β2 in TGF-β1-treated endometrial stromal cells. No effect on 
TGF-β2 levels was observed in controls and TGF-β2-treated cells (**=P<0.01, n=6).  
 
In summary, in all cell lines studied, there was increased TGF-β2 secretion in     
TGF-β1-treated cells. No effect was observed in control cells and cells treated with 
TGF-β2. Endometriotic epithelial cells, 12ZVK, secreted 2-fold more TGF-β2 
compared to endometrial epithelial cells, HES, after stimulation with TGF-β1. 
Endometriotic stromal cells, 22B, secreted 3-fold more TGF-β2 compared to 
endometrial stromal cells T-HESC. TGF-β1-treated T-HESC as well as TGF-β-
treated primary endometrial stromal cells secreted almost the same amount of TGF-
β2.   
 
3.10 Influence of TGF-β1 or TGF-β2 on Secretion of TGF-β1 by Endometrial and 
Endometriotic Cells in vitro 
To investigate the influence of TGF-β1 or TGF-β2 on secretion of TGF-β1 by 
endometrial and endometriotic cells, we quantitated TGF-β1 secretion by cells. 
The endometrial and endometriotic cells were treated with TGF-β1 or TGF-β2 
(10ng/ml), respectively. Then cell supernatants were collected after 48 hours upon 
TGF-β1 or TGF-β2 treatment to quantitate TGF-β1.  
Treatment of cells with TGF-β1 or TGF-β2 increased secretion of TGF-β1 in         
TGF-β1-treated cells. No effect on TGF-β1 levels was observed in controls and TGF-
β2-treated cells (Figs. 51-53). 
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Figure 51. Treatment of endometrial cells (HES and T-HESC) with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, increased secretion of TGF-β1 in TGF-β1-treated cells. Endometrial stromal cells, T-
HESC, secreted 2-fold more TGF-β1 compared to endometrial epithelial cells HES. No effect on TGF-
β1 levels was observed in controls and TGF-β2-treated cells in endometrial cells (*=P<0.05, n=6). 
 
 
 
 
 
 
 
 
 
 
Figure 52. Treatment of endometriotic cells (12ZVK and 22B) with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, increased secretion of TGF-β1 in TGF-β1-treated cells. Endometriotic stromal cells, 22B, 
secreted 1.5-fold more TGF-β1 compared to endometriotic epithelial cells 12ZVK. No effect on TGF-
β1 levels was observed in controls and TGF-β2-treated endometriotic cells (*=P<0.05, n=6). 
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Figure 53. Treatment of primary endometrial stromal cells with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, increased secretion of TGF-β1 in TGF-β1-treated endometrial stromal cells. No effect on 
TGF-β1 levels was observed in controls and TGF-β2-treated cells (*=P<0.01, n=6). 
 
3.11 Influence of TGF-β1 or TGF-β2 on Interaction of TβRI, TβRII and TβRIII 
Receptors on Endometrial and Endometriotic Cells in vitro (Signalosome 
analysis) 
To quantify and analyze the interaction of the TβRI, TβRII and TβRIII receptors on 
primary endometrial cells and other cell lines, we used the Proximity Ligation Assay 
(PLA). PLA enables detection, visualization and quantification of protein interactions 
in tissue and cell samples. The PLA principle is shown in Fig. 54  
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Figure 54. Principle of Duolink In Situ PLA assay (adapted from http//www.Olink.com) 
 
The resulting fluorescence in each single-molecule amplification product is visible as 
a distinct spot under a fluorescence microscope (Soderberg et al., 2006; Jurvious et 
al., 2007). 
In our experiments, we applied in situ PLA (Duolink) with a combination of antibodies 
that allows the detection of TβRII/TβRIII and TβRI/TβRII interaction only when these 
are in close proximity upon treatment of cells with TGF-β1 or TGF-β2. The details of 
the antibodies used are indicated in Table 1. 
Step 1: A pair of primary antibodies raised in different species 
bind to the target antigens of interest 
 
Step 2: A pair of species-specific secondary antibodies 
called, PLA probes (PLUS and MINUS), bind to their 
respective primary antibody 
Step 3: Two oligonucleotides are joined by a ligase to form 
a circular molecule only when the two PLA probes 
are at a close proximity 
 
Step 4:  A polymerase amplifies the circle forming several 
hundred-fold replication of DNA circle            
            
 
Step 5:  Labeled complementary oligonucleotide probes  bind 
the synthesized DNA strand allowing the product to be 
visualized with a fluorescence microscope 
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For the PLA assay, 20,000 cells on 8-well chamber slides were treated with or 
without TGF-β1 or TGF-β2 for 24 hours and afterwards fixed and permeabilized. A 
pair of primary antibodies against TβRII and TβRIII or TβRI and TβRII was used to 
detect the complexes (Table 1). Controls were performed by omissions of the primary 
antibodies. Phase contrast images showed the exact localization of the signals. 
Images were obtained with the inverse microscope FSX 100 (Olympus) using the 
Olympus FSX-BSW software. Images were processed with Adobe Photoshop. The 
quantity of PLA signals was counted and the average number of spots per cell was 
presented graphically.  
The results showed interaction of TβRII and TβRIII or TβRI and TβRII in all cell lines 
as shown by the red fluorescent spots. The quantity of red fluorescent spots varied in 
the cell lines depending on the intensity of TGF-βs/TβRs interaction. Control cells 
and cells without primary antibodies showed no TβR interactions (Figs. 55-62). 
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3.11.1 Interaction of TβRII and TβRIII Receptors on HES Cells  
 E 
 
 
 
 
 
 
 
 
 
 
Figure 55. Interaction of TβRII/III on HES cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1 (C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). Antibodies 
against TβRII and TβRIII were used to detect the TβRII/TβRIII receptor complexes (A, C, E and G). 
The phase contrast image (G) showed the exact location of the receptor interaction on the cells. 
Omission of the primary antibodies was used as controls (B, D, F). Signals were counted and the 
average number of spots per cell is presented in the graph (H). 
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Treatment of HES cells with TGF-β1 or TGF-β2 (10ng/ml) induced interaction of 
TβRII and TβRIII receptors. The interaction was stronger in TGF-β2- compared to 
TGF-β1-treated cells and the receptor complex interactions were localized mainly in 
the proximity of the membranes. Untreated cells and cells without primary antibodies 
showed no receptor interactions. 
 
3.11.2 Interaction of TβRI and TβRII Receptors on HES  Cells  
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Figure 56. Interaction of TβRI/II on HES cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1 (C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). Antibodies 
against TβRI and TβRII were used to detect the TβRI/TβRII receptor complexes (A, C, E and G). The 
phase contrast image (G) showed the exact location of the receptor interaction on the cells. Omission 
of the primary antibodies was used as controls (B, D, F). Signals were counted and the average 
number of spots per cell is presented in the graph (H). 
 
Treatment of HES cells with TGF-β1 or TGF-β2 (10ng/ml) induced interaction of TβRI 
and TβRII receptors. The interaction was moderate in both TGF-β1- and TGF-β2-
treated cells and the receptor complex interactions were localized mainly found in the 
proximity of the membranes. Untreated cells and cells without primary antibodies 
showed no receptor interaction. All experiments were performed only once.  
 
3.11.3 Interaction of TβRII and TβRIII Receptors on T-HESC Cells  
 
 
 
 
 
+ TβRII and TβRIII 
 
no antibodies  
+ TβRII and TβRIII 
 
 
B 
B
F G
+ TGF-β1 
 
+ TGF-β2 
 
A 
x200 
B
x200
FE 
DC 
G
x200 x200
x200 x200 
F G
x200 x200 x200x200 x200 
E 
Control 
 98
 
 
 
 
 
 
 
 
 
Figure 57. Interaction of TβRII/III on T-HESC cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. 
Cells were treated with TGF-β1 (C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). 
Antibodies against TβRII and TβRIII were used to detect the TβRII/TβRIII receptor complexes (A, C, E 
and G). The phase contrast image (G) showed the exact location of the receptor interaction. Omission 
of the primary antibodies was used as controls (B, D, F). Signals were counted and the average 
number of spots per cell is presented in the graph (H). Similar results were observed with primary 
endometrial stromal cells (data not shown). 
 
Treatment of T-HESC cells with TGF-β1 or TGF-β2 (10ng/ml) induced interaction of 
TβRII and TβRIII receptors. The interaction was stronger in TGF-β2- compared to 
TGF-β1-treated cells and the receptor complex interactions were localized mainly in 
the proximity of the membranes. Untreated cells and cells without primary antibodies 
showed no receptor interaction. 
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3.11.4 Interaction of TβRI and TβRII Receptors on T-HESC  Cells  
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Interaction of TβRI/II on T-HESC cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1 (C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). Antibodies 
against TβRI and TβRII were used to detect the TβRI/TβRII receptor complexes (A, C, E and G). The 
phase contrast image (G) showed the exact location of the receptor interaction. Omission of the 
primary antibodies was used as controls (B, D, F). Signals were counted and the average number of 
spots per cell is presented in the graph (H). Similar results were observed with primary endometrial 
stromal cells (data not shown). 
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Treatment of T-HESC cells with TGF-β1 or TGF-β2 (10ng/ml) induced interaction of 
TβRI and TβRII receptors. The interaction was moderate in both TGF-β1- and TGF-
β2-treated cells and the receptor complex interactions were mainly revealed in the 
proximity of the membranes. Untreated cells and cells without primary antibodies 
showed no receptor interaction. All experiments were performed only once. 
 
3.11.5 Interaction of TβRII and TβRIII Receptors on 12ZVK  Cells  
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Figure 59.  Interaction of TβRII/III on 12ZVK cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1 (C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). Antibodies 
against TβRII and TβRIII were used to detect the TβRII/TβRIII receptor complexes (A, C, E and G). 
The phase contrast image (G) showed the exact location of the receptor interaction. Omission of the 
primary antibodies was used as controls (B, D, F). Signals were counted and the average number of 
spots per cell is presented in the graph (H). 
 
In summary, treatment of 12ZVK cells with TGF-β1 or TGF-β2 (10ng/ml) induced 
interaction of TβRII and TβRIII receptors. The interaction was stronger in TGF-β2- 
compared to TGF-β1-treated cells and the receptor complex interactions were mainly 
located in the proximity of the membranes. Untreated cells and cells without primary 
antibodies showed no receptor interaction. 
 
3.11.6 Interaction of TβRI and TβRII Receptors on 12ZVK  Cells      
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Figure 60. Interaction of TβRI/II on 12ZVK cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1 (C, D) or TGF-β2 (E, F) for 30 minutes or left untreated (A, B). Antibodies 
against TβRI and TβRII were used to detect the TβRI/TβRII receptor complexes (A, C ,E and G). 
Omission of the primary antibodies was used as controls (B, D, F). The phase contrast image (G) 
showed the exact location of the receptor interaction. Signals were counted and the average number 
of spots per cell is presented in the graph (H). 
 
In summary, treatment of 12ZVK cells with TGF-β1 or TGF-β2 (10ng/ml) induced 
interaction of TβRI and TβRII receptors. The interaction was moderate in both TGF-
β1- and TGF-β2-treated cells. The receptor complex interactions were mainly in the 
proximity of the membranes. Untreated cells and cells without primary antibodies 
showed no receptor interaction.  
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3.11.7 Interaction of TβRII and TβRIII Receptors on 22B Cells  
                  
 
 
 
 
 
 
 
 
 
Figure 61. Interaction of TβRII/III on 22B cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1(C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). Antibodies 
against TβRII and TβRIII were used to detect the TβRII/TβRIII receptor complexes ( A, C, E and G). 
The phase contrast image (G) showed the exact location of the receptor interaction. Omission of the 
primary antibodies was used as controls (B, D, F). Signals were counted and the average number of 
spots per cell is presented in the graph (H). 
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In summary, treatment of 22B cells with TGF-β1 or TGF-β2 (10ng/ml) induced 
interaction of TβRII and TβRIII receptors. The interaction was stronger in TGF-β2- 
compared to TGF-β1-treated cells and the receptor complex interactions were mainly 
found in the proximity of the membranes. Untreated cells and cells without primary 
antibodies showed no receptor interaction. 
 
3.11.8 Interaction of TβRI and TβRII Receptors on 22B Cells             
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Figure 62. Interaction of TβRI/II on 22B cells after TGF-β1 or TGF-β2 (10ng/ml) stimulation. Cells 
were treated with TGF-β1 (C, D) or TGF-β2 (E-G) for 30 minutes or left untreated (A, B). Antibodies 
against TβRI and TβRII were used to detect the TβRI/TβRII receptor complexes (A, C, E and G). The 
phase contrast image (G) showed the exact location of the receptor interaction. Omission of the 
primary antibodies was used as controls (B, D, F). Signals were counted and the average number of 
spots per cell is presented in the graph (H). 
 
 
Treatment of 22B cells with TGF-β1 or TGF-β2 (10ng/ml) induced interaction of TβRI 
and TβRII receptors. The interaction was moderate in both TGF-β1- and TGF-β2-
treated cells and the receptor complex interactions were mainly located in the 
proximity of the membranes. Untreated cells and cells without primary antibodies 
showed no receptor interaction. 
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4 Discussion 
 
TGF-βs are one of the most essential growth factors involved in cell differentiation, 
proliferation, motility and apoptosis in various cell types. Given the great importance 
of TGF-βs in the process of menstruation and endometriosis (Pizzo et al., 2002; 
Gaide Chevronnay et al., 2008), TGF-βs and their receptors (TβRs) are suspected to 
be involved in establishment and maintenance of endometriosis (Omwandho et al., 
2010). 
In this study, we investigated the influence of TGF-βs on cell numbers, regulation of 
some proteins essential in endometriosis and TGF-β receptor interactions in 
endometrial, endometriotic cells and primary endometrial stromal cells. Furthermore, 
we studied the signaling pathways of TGF-βs and possible cross-talks with other 
pathways, especially the Smad-dependent and Smad-independent pathways were 
investigated in this study. Also the possible cross-talk between TGF-βs and BMPs 
and TGF-β/TβR in endometrial and endometriotic cells were investigated for the first 
time.  
 
4.1 Role of TGF-βs in Endometrial and Endometriotic Cells and Primary 
Endometrial Stromal Cells 
4.1.1 Influence of TGF-βs on Cell Numbers  
Cell numbers in tissues are usually determined by the rate of proliferation and 
apoptosis (Sommer and Rao, 2002). Up to date, it remains unclear how the TGF-β 
pathways results in induction of apoptosis. Because the effects of TGF-βs on 
endometrial and endometriotic cells numbers are controversial, we investigated the 
effects of TGF-βs on endometrial and endometriotic cell numbers after treatment with 
TGF-β1 and TGF-β2. TGF-βs decreased the cell numbers in all cell lines studied. 
Our results agree with those of Meresman et al. (2003) and Sui. (2012)  who showed 
that the influence of TGF-βs on cell numbers decrease when the initial cell number is 
high. Of note,  in this study, the reduction of cell numbers was higher in endometrial 
cells compared to endometriotic cells, suggesting that possibly the endometriotic 
cells are less responsive to stimulation by TGF-βs as similarly shown for cancer cells 
and will be discussed later. 
Furthermore, we showed that the effect of TGF-β1 or TGF-β2 on cell numbers was 
completely blocked with a TβR1 inhibitor, while a Smad3 inhibitor blocked TGF-βs 
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effects on cell numbers only partially. Our results further showed that the Smad-
dependent pathway is utilized in the TGF-β-dependent reduction of cell numbers in 
endometrial and endometriotic cells as also shown by Sui. (2012). 
Apart from cell proliferation, other factors like apoptosis or cell attachment might 
influence the cell numbers as will be explained in detail in the following sections. 
 
4.1.2 Effects of TGF-βs on Apoptosis  
According to Garcia-Velasco et al. (1999), the escape of endometrial fragments from 
apoptosis as they enter/transit the peritoneal cavity is very important for their survival. 
Gebel et al. (1998) showed greatly reduced apoptosis in sloughed endometrial cells 
from women who develop endometriosis, implying that high numbers of surviving 
cells can enter the peritoneal cavity. Similarly, apoptosis was found to decrease as 
the severity of endometriosis increased (Dmowski et al., 2001). Also, Bcl-2 protein 
expression was found to be increased in proliferative eutopic endometrium in women 
with endometriosis and FasL was highly expressed by endometriotic tissues 
(Meresman et al., 2000; Garcia-Velasco et al., 2002). 
Up to date, the connection between the TGF-β pathway and the apoptotic pathways 
still remains unclear. Since TGF-βs are increased in the serum and peritoneal fluid of 
women with endometriosis and their levels are enhanced markedly with the severity 
of the disease (Pizzo et al., 2002; Garcia-Velasco et al., 2002), we suspect that TGF-
βs possibly induce apoptosis which might play an important role in the pathogenesis 
of endometriosis by increasing survival rate of endometriotic cells because less cells 
die upon TGF-β treatment. In our experiments, we wanted to investigate whether or 
not TGF-βs exert an apoptotic effect on human endometrial and endometriotic cells 
and if yes, which apoptotic pathways are involved. We quantified phosphatidylserine 
on the outer membrane surface, the inner mitochondrial membrane potential, and 
activation of Caspase 3/7 proteins. The three parameters are important because they 
can be used to discriminate between necrosis and apoptosis. 
The results showed that TGF-β1 or TGF-β2 increased phosphatidylserine, decreased 
the inner mitochondrial membrane potential and increased Caspase 3/7 levels in 
endometrial and endometriotic cells. However, in our results, TGF-β1- or TGF-β2-
induced apoptosis did not show any significant differences among the four cell lines 
and the primary endometrial stromal cells. This implies that concerning the aspect of 
 108
apoptosis, endometrial cells, endometriotic cells, as well as primary endometrial 
stromal cells, response to the stimulation by TGF-βs in a similar manner. 
Furthermore, we showed that the effect of TGF-β1 or TGF-β2 on apoptosis was 
completely blocked by a TβR1 inhibitor, while a Smad3 inhibitor blocked TGF-β-
induced apoptosis in all cells only partially. Our results indicate that the Smad-
dependent pathway is mainly utilized in TGF-β-induced apoptosis in endometrial and 
endometriotic cells. Thus, we showed that both the mitochondrial apoptotic pathway 
(intrinsic) and the death receptor apoptotic pathway (extrinsic) are involved in TGF-β-
induced apoptosis in endometrial and endometriotic cells. Our results further agrees 
with Sánchez-Capelo (2005) who showed that TGF-βs cooperate with the death 
receptor apoptotic pathway (Fas), the mitochondrial apoptotic pathway (Bcl-2) and a 
number of intracellular apoptotic modulators in mediating apoptosis.  
Since, the effects of TGF-βs on apoptosis are similar in both endometrial and 
endometriotic cell numbers, we suppose that other factors like the amount of Smad3 
phosphorylation or PAI-1 levels might possibly affect cell numbers or proliferation as 
will be discussed in the following sections.  
 
4.1.3 The Role of TGF-βs in Phosphorylation of Smad3  
Despite many studies on Smad proteins, there is so far no direct evidence implicating 
Smad3 as an intermediate protein in TGF-β signaling pathway in endometriotic cells. 
Luo et al. (2003) showed that TGF-β1 induced phosphorylation of Smad3 in 
endometrial epithelial cell line (HES) and endometrial stromal cells (ESC) in a dose-
dependent manner. He quantified Smad3 phosphorylation in the HES cell line and 
endometrial stromal cells using Western blot, IHC and semiquantitative Polymerase 
Chain Reaction. The effect of TGF-β1 on pSmad3 induction was in part abrogated 
upon treatment of HES and ESC cells with TGF-β type II receptor antisense (Luo et 
al., 2003). Given the fact that the six developmental stages leading to endometriosis 
are similar to tumourigenesis (Omwandho et al., 2010), also Smad proteins have 
been found to be frequently mutated in cancer cells (Liu et al., 1997). Moreover, 
Smad3 is frequently downregulated in cancer (Jones et al., 2008). Thus, we 
hypothesized that the effects of TGF-βs on Smad3 phosphorylation in endometriosis 
might be similar to those observed in tumour cells. We further hypothesized that the 
effects of TGF-βs on Smad3 phosphorylation might have an indirect impact on cell 
numbers in endometrial or endometriotic cells. In our experiments, we quantified 
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Smad3 phosphorylation with a phospho-Smad3 ELISA upon TGF-β1 or TGF-β2 
stimulation.  
Our results showed that TGF-βs stimulated phosphorylation of Smad3 in 
endometrial, endometriotic cell lines and primary endometrial stromal cells. Our 
results agree with those of Luo et al. (2003) who also observed phosphorylation of 
Smad3 in HES and endometrial stromal cells upon stimulation with TGF-β1. 
Interestingly, we also demonstrated that Smad3 phosphorylation was significantly 
higher in endometrial cells compared to endometriotic cells upon stimulation with 
TGF-βs, suggesting that possibly the endometriotic cells are somehow less 
responsive to stimulation by TGF-βs. Furthermore, we showed that the effects of 
TGF-β1 or TGF-β2 on pSmad3 induction were abrogated completely following 
treatment of cells with Smad3 or TGF-β type I receptor inhibitors. Thus, our results 
provide strong evidence that Smad3 is involved in TGF-β-dependent responses and 
we suppose that its activity is downregulated in endometriosis. These observations 
might explain the reduced responsiveness in reduction of cell numbers of 
endometriotic cells upon stimulation with TGF-βs. However, expression levels of 
Smad3 need to be determined in all cell lines studied. 
Liu et al. (1997) showed that Smad3 phosphorylation might be involved in TGF-β-
dependent growth inhibition and activation of genes encoding PAI-1 protein in lung 
epithelial cells. Also, constitutive phosphorylation of Smad3 was associated with 
increased transcription of PAI-1 genes in activated hepatic stellate cells (Inagaki et 
al., 2001). Czekay et al. (2011) observed that PAI-1 lowered attachment of cells to 
ECM through inhibition of uPAR-vitronectin interaction. Based on these observations, 
we hypothesised that PAI-1 might have an effect on endometrial and endometriotic 
cell numbers since it is directly correlated to Smad3 phosphorylation. In our 
experiments, we quantified secretion of PAI-1 by endometrial and endometriotic cells 
as described in the next chapter.  
 
4.1.4 The Role of TGF-βs in PAI-1 Secretion  
PAI-1 is the major inhibitor of tissue/urokinase plasminogen activator (tPA/ uPA) and 
is important in extracellular matrix turnover (Vial and Longo, 2008). Expression of 
PAI-1 and uPA was found to be higher in endometriotic and endometrial tissue of 
women with endometriosis compared to tissue of women without endometriosis 
(Bruce et al., 1998; 2004). Also, PAI-1 levels were higher in ectopic tissues compared 
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to eutopic tissues of women with endometriosis (Bruce et al., 2004) indicating that 
PAI-1 is important in the pathogenesis of endometriosis. 
In our experiments, we wanted to investigate whether or not PAI-1 is involved in 
endometriosis and which pathways are concerned. We compared secretion of PAI-1 
in endometrial and endometriotic cells upon stimulation with TGF-β1 or TGF-β2 in 
vitro. We demonstrated that endometriotic cells secreted more PAI-1 than 
endometrial cells. Since PAI-1 was found to favour detachment of cells from various 
substrates and also to increase their motility (Akkawi et al., 2006; Czekay et al., 
2011), then increased secretion of PAI-1 in endometriotic cells compared to 
endometrial cells observed in our experiments suggests that endometriotic cells are 
more easily detached and thus more cells are possibly retrograded to ectopic sites 
hence enhancing establishment of endometriosis. 
Furthermore, we showed that the effects of TGF-β1 or TGF-β2 on PAI-1 secretion 
were completely blocked by a TβR1 inhibitor, while a Smad3 inhibitor blocked PAI-1 
only partially. Our results further affirm that the Smad-dependent pathway is mainly 
utilized in TGF-β-dependent PA1-1 secretion by endometrial and endometriotic cells. 
Since TGF-β-dependent PA1-1 secretion was observed to be mainly Smad-
dependent, we hypothesized that by the use of PAI-1 secretion, we might study 
possible cross-talks between the TGF-βs and BMP pathways. Both pathways utilize 
Smad proteins as their signal transducers from the cell surface to the nucleus. The 
cross-talk between the two pathways is described in the following section. 
 
4.1.5 Cross-talk of the TGF-β and BMP Pathways.  
The BMP ligands can bind to any of the three type II receptors (BMPRII, ActRIIa and 
ActRIIb) and the three type 1 receptors (ALK-2, ALK-3 and ALK-6). Upon binding, the 
constitutively active type II receptor phosphorylates type 1 receptor. The activated 
type 1 receptor phosphorylates the BMP-responsive Smad proteins namely Smad1, 
Smad5 and Smad8. The activated Smads bind Smad4 either in the cytoplasm or in 
the nucleus to facilitate signaling (Yu et al., 2008).  
Perturbations of both BMP and TGF-β signaling have been reported to cause distinct 
and also overlapping phenotypic bone diseases (Jansens et al., 2000). Furthermore, 
alterations of both TGF-β and BMP pathways have been associated with vascular 
diseases like pulmonary hypertension (Boeck and Dijke, 2011). These two 
observations clearly indicate that the two pathways might be cross-talking at some 
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point. Thus, it might be crucial to determine whether or not a cross-talk exists 
between the two pathways in endometrial and endometriotic cells. This will enhance 
further understanding of the roles of the two pathways in the pathogenesis of 
endometriosis. 
In our experiments, we used a general BMP inhibitor LDN-193189 selectively 
inhibiting the BMP type 1 receptors ALK-2, ALK-3 and ALK-6 and thus blocking BMP-
mediated phosphorylation of Smad1/5/8. In addition, we used distinct inhibitors for 
ALK-2, ALK-3 and ALK-6 separately to determine the possible cross-talk of the TGF-
β and BMP pathways upon TGF-β1 or TGF-β2 stimulation. 
Our results showed that LDN-193189 as well as the ALK-2 inhibitor completely 
inhibited the TGF-β-induced secretion of PAI-1 in endometrial and endometriotic 
cells. Interestingly, both ALK-3- and ALK-6-inhibitors reduced the TGF-β-induced 
secretion of PAI-1 only partially. Our results suggest a cross-talk between the TGF-β 
and BMP pathways and also that the Smads are the most important intracellular 
transducers of TGF-β and BMP signals from the receptors to the nucleus.   
Furthermore, we also showed for the first time that an ALK-2 inhibitor completely 
blocked the TGF-β-induced secretion of PAI-1 in endometrial and endometriotic cells. 
Our results are in agreement with those of Chen et al. (2003) and Bharathy et al. 
(2008) who showed that TGF-βs can also strongly but only transiently phosphorylate 
Smad1, Smad5 and Smad8 in endothelial, epithelial, fibroblasts and cancer-derived 
cells. Our results are further supported by Barnet et al. (2002) who showed that TGF-
βs signals via ALK-2 and ALK-5 in chick atrial cells and Olivey et al. (2006) who 
implicated ALK-2 in the TGF-βs stimulated epithelial-mesenchymal transformation in 
mammary glands of the mouse. 
To further understand other cross-talks between the TGF-β and BMP pathways, we 
measured secretion of inhibin B which is a marker for the functionality of the BMP 
pathway as described in the following section. 
 
4.1.6 The Effect of the TGF-βs on Inhibin B Secretion  
Inhibin B is a member of the TGF-β superfamily and regulates reproduction. Inhibin B 
secretion is a marker for the functionality of the BMP pathway.  Petraglia et al. (1998) 
showed that inhibin B is found in peritoneal fluid and serum of women with or without 
endometriosis. They showed that there was no significant difference in inhibin B 
levels in women with and without endometriosis although inhibin B levels were higher 
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in the peritoneal fluid compared to serum in women with or without endometriosis. 
Cultured endometrial stromal and epithelial cells also expressed inhibin B with no 
significant differences between women with or without endometriosis (Petraglia et al., 
1998). Since inhibin B was expressed by both endometrial and endometriotic cell 
cultures, we hypothesized that by treating endometrial or endometriotic cells with 
TGF-β1 or TGF-β2, it might be possible to elucidate whether TGF-β cross-talks with 
the BMP pathway in these cells with respect to inhibin B secretion.  
In our experiments, we stimulated endometrial or endometriotic cells with TGF-β1 or 
TGF-β2 and measured inhibin B secretion. Our results showed that TGF-β1 or TGF-
β2 slightly reduced inhibin B secretion by HES cells and primary endometrial stromal 
cells with no effects observed in the other cell lines. There were no significant 
differences between endometrial and endometriotic cells. Thus, the result shows that 
inhibin B is not a common protein as PAI-1 in both BMP and TGF-β pathways. 
 
4.1.7 Effects of TGF-βs on Interaction of TβRI, TβRII and TβRIII Receptors 
TGF-βs are secreted into the extracellular matrix as a latent protein complex and only 
after activation they become biologically active (Rebecca, 2000). Once activated, the 
TGF-βs bind to their high affinity cell surface receptors (TβRI, TβRII and TβRIII). 
However, TβRI and TβRII were found to be inactivated in various human tumors 
(Levy and Hill, 2006). 
Given the fact that the stages for endometriosis resemble closely metastasis thus, we 
suspect that the relevance of TGF-βs in metastasis might be similar in endometriosis.  
In our experiments, we characterized the TGF-β signalosome in endometrial and 
endometriotic cells. Upon stimulation with TGF-β1 or TGF-β2, TβRII and TβRIII or 
TβRI and TβRII interaction were quantified by in situ Proximity Ligation Assay. 
Expression of TβRIII by cell surface ELISA was also further investigated.   
Our results showed that stimulation of endometrial and endometriotic cells with TGF-
β1 or TGF-β2 increased TβRIII expression on the cell surfaces. Of note, stromal cells 
showed higher expression of TβRIII compared to epithelial cells in both endometrial 
and endometriotic cells. We observed no significant differences in TβRIII receptor 
expression between endometrial and endometriotic cells. Our results are in contrast 
to the observations by Dong et al. (2007), Hempel et al. (2007), Turley et al. (2007) 
and Gordon et al. (2008) who showed reduction of TβRIII receptor expression in 
pancreatic, breast, prostrate and ovarian cancers. The increased TβRIII receptor 
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expression upon TGFβ stimulation in both endometrial and endometriotic cells in this 
study might be attributed to the fact that unlike cancer cells, endometriotic cells still 
form functional glands.  
Stimulation of endometrial and endometriotic cells with TGF-β1 or TGF-β2 increased 
TβRII and TβRIII interaction. Interestingly, the interaction was stronger in TGF-β2-
treated cells compared to TGF-β1-treated cells. This shows that TGF-β2 has a higher 
sensitivity to TβRIII compared to TGF-β1. Also, endometrial cells showed stronger 
interaction compared to endometriotic cells. Furthermore, we observed a moderate 
TβRI/TβRII interaction in TGF-β1-treated as well as in TGF-β2-treated endometrial 
cells which was slightly stronger compared to endometriotic cells. Overall our results 
showed that the TGF-βs exert a stronger influence in endometrial cells compared to 
endometriotic cells with respect to the interaction of the high-affinity TGF-β receptors 
upon TGF-β treatment. This might explain the stronger reduction in cell numbers of 
endometrial cells due to stronger receptor interactions on these cells. Thus we 
predict that the weak interaction of TβRI, TβRII and TβRIII receptors expression in 
endometriotic cells might be associated with the pathogenesis of endometriosis. Our 
results agrees with those of Meng et al. (2011) who observed a decreased 
expression of TβRII and TβRIII in oral squamous cell carcinoma and oral carcinoma-
associated fibroblasts upon TGF-β1 treatment. Also TβRIII expression decreased 
during breast cancer and lung cancer progression (Dong et al., 2007; Malkoski et al., 
2012). In addition, Chen et al. (1997) and Kim et al. (1999) observed a decreased 
expression of TβRI, TβRII and TβRIII in some human cancers. In summary, the 
different expression levels of TβRs in endometrial cells compared to endometriotic 
cells suggest an involvement in the pathogenesis of endometriosis. 
 
4.1.8 Characteristic Differences between Endometrial and Endometriotic Cells 
and Tissues 
Several epithelial cell markers have been used in tumor biology by pathologists to 
characterize metastatic cells; most investigators use a panel of epithelial markers 
which are like fingerprints for certain tissues. In this study we characterized 
endometrial and endometriotic tissues using antibodies for Cytokeratin 18 (CK18) 
and Mucin-1 (MUC1) proteins which are expressed on epithelial cells and polarized 
epithelial cells, respectively. We characterized endometrial biopsies obtained from 
patients with or without endometriosis and we assessed endometrial glands from the 
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endometrium and the ovary. Our results showed that both proteins are expressed in 
the endometrial and endometriotic glands of both the endometrium and the ovary. 
The identical expression profile of MUC1 and CK 18 in both tissues examined 
suggests a common origin. Thus, our data are consistent with Sampson’s hypothesis, 
who postulated that all endometriotic lesions result from dissemination of endometrial 
cells, however, more markers need to be tested to fully characterise endometrial and 
endometriotic tissues. 
 
4.1.9 TGF-β Signaling in Endometrial Cells, Endometriotic Cells and Primary 
Endometrial Stromal Cells 
The Smad-dependent pathway is the main pathway of TGF-β signaling and is 
activated by phosphorylation of TβRI which in turn phosphorylates Smad2/3 
(Massagué and Wotton, 2000).  
In our experiments, we demonstrated a reduction in cell numbers, increased PAI-1 
secretion, increased Smad3 phosphorylation and increased apoptosis upon 
stimulation of endometrial, endometriotic cells and primary endometrial stromal cells 
with TGF-βs. In addition, we studied both Smad-dependent and Smad-independent 
pathways by using specific inhibitors that target downstream cascades of TGF-β 
signaling in endometrial, endometriotic cells and primary endometrial stromal cells. 
 
4.1.10 The Smad-dependent Pathway in TGF-β Signaling in Endometrial Cells, 
Endometriotic Cells and Primary Endometrial Stromal Cells 
TGF-βs can also activate Smad1, Smad5 and Smad8 (BMP-responsive Smads) in 
endothelial cells, epithelial cells, fibroblasts and epithelium-derived cancer cells 
(Bharathy et al., 2008; Liu et al., 2009). 
In our study, we investigated the Smad-dependent pathway by using LY364947 and 
SiS3 inhibitors that selectively block the kinase activity of TβR1 and Smad3 
phosphorylation, respectively. Our results showed that LY364947 can completely 
inhibit reduction in cell numbers, block increased PAI-1 secretion, inhibit increased 
Smad3 phosphorylation and block increased apoptosis upon stimulation of 
endometrial, endometriotic cells and primary endometrial stromal cells with TGF-βs. 
The Smad3 inhibitor SiS3 completely blocked the TGF-β-induced Smad3 
phosphorylation but only partially blocked reduction in cell numbers, increased PAI-1 
secretion, and increased apoptosis, implying that Smad2 is also involved in TGF-β 
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signaling. These data further supports that Smads are the most important mediators 
of TGF-β signaling from the receptors to the nucleus as published by Chen et al. 
(2003). 
 
4.1.11 The Smad-independent Pathways in TGF-β Signaling in Endometrial and 
Endometriotic Cell Lines and Primary Endometrial Stromal Cells 
A number of Smad-independent pathways which modulate the signal transduction by 
TGF-βs have been described (Yue and Mulder, 2000; Massagué and Chen, 2000; 
Moustakas and Heldin, 2005; Zhang et al., 2009). For example, Engel et al. (1999) 
showed that TGF-β-activated JNK phosphorylated Smad3 inducing its nuclear 
translocation. TGF-β1 mediated activation of TGF-β2 expression in human hepatic, 
murine fibroblasts and keratinocytes cells (Bascom et al., 1989; Shimada et al., 
2011). Also, TGF-β2 is significantly upregulated in breast cancer cells (Dave et al., 
2011). The mechanisms used by TGF-β1 to activate TGF-β2 have not been fully 
understood. In our experiments, we investigated the influence of TGF-β1 or TGF-β2 
on secretion of TGF-β1 or TGF-β2 by endometrial and endometriotic cells. 
Our results showed increased TGF-β2 secretion in TGF-β1-treated cells but no 
effects upon treatment with TGF-β2. Of note, endometriotic epithelial cells as well as 
endometriotic stromal cells secreted more TGF-β2 compared to endometrial 
epithelial and stromal cells, respectively. Thus, the increased expression of TGF-β2 
in endometriotic cells compared to endometrial cells suggests the possible TGF-β 
involvement in pathogenesis of endometriosis. Our results concur with those of Dave 
et al. (2011) who observed higher expression of TGF-β2 in advanced stages of 
breast cancer. Also our results agree with the observations by Shimada et al. (2011) 
who showed that TGF-β1 mediated activation of TGF-β2 in human hepatic cells. Of 
note, TGF-β1 treated stromal T-HESC and primary endometrial stromal cells 
secreted almost the same amount of TGF-β2.  
Furthermore we analyzed the mechanisms used by TGF-β1 in mediating activation of 
TGF-β2 by investigating several Smad-dependent and Smad-independent pathways 
using specific inhibitors. Our results showed that only the JNK inhibitor blocked TGF-
β1-induced secretion of TGF-β2 partially by about 50% (data not shown). Our results 
possibly suggest that TGF-β1 might stimulate secretion of TGF-β2 by the JNK 
pathway. Our results concur with those of Li and Wicks. (2001) who observed that 
JNK interacts with the retinoblastoma protein in stimulating TGF-β2. 
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Also, we observed increased TGF-β1 secretion in TGF-β1 treated cells indicating 
autostimulation. However, no effect on TGF-β1 secretion was observed in both 
controls and TGF-β2 treated cells. These results possibly indicate that TGF-β1 
autostimulated itself through the JNK pathway. Our results are in agreement with 
those of Pardouk and Derynck, (2004) and Ventura et al. (2004) who showed that 
JNK regulates expression of TGF-β1 in fibroblasts.  Further support for our results is 
shown by Zhang et al. (2006) who found that TGF-β1 autoinduced itself through 
JNK/p38 signaling in proximal tubular epithelial cells. 
 
4.2 Conclusions 
In this study, we investigated the influence of TGF-βs on endometrial, endometriotic 
cell lines and primary endometrial stromal cells in vitro. The findings showed that 
TGF-βs dramatically increased secretion of PAI-1, Smad3 phosphorylation, apoptosis 
and TBRIII receptor expression on endometrial, endometriotic cell lines and primary 
endometrial stromal cells. We also demonstrated reduction in cell numbers in all cells 
studied. The TGF-β-induced strong increase in PAI-1 secretion in endometriotic cells 
compared to endometrial cells suggest that PAI-1 might cause also an increased 
breakdown of endometrial tissue during menstruation, possibly resulting in increased 
invasiveness and implantation of endometrial tissues at ectopic sites after retrograde 
menstruation. Our findings that reduced Smad3 phosphorylation and reduced TBRI, 
TBRII and TBRIII interactions in endometriotic cells compared to endometrial cells 
indicate that endometriotic cells might become somehow less responsive to TGF-β 
signals. Furthermore, this might possibly also explain for example why there was a 
lower reduction in cell numbers in endometriotic cells compared to endometrial cells 
upon treatment with TGF-βs. Also, the results obtained with MUC1 and CK 18 
expression in nearly all endometrial glands as well as ovarian cysts indicate that 
endometrial cells are disseminated like tumor cells thus further corroborating the 
importance of the results obtained with PAI-1 and the TGF-βs.  
Our study also affirmed that the Smad pathway is the main pathway of TGF-β 
signaling in endometrial, endometriotic cell lines and primary endometrial stromal 
cells. Our results also showed for the first time that ALK-2 acts as a link between 
BMP and TGF-β signaling in endometrial, endometriotic cell lines and primary 
endometrial stromal cells. Furthermore, we reported for the first time that the JNK 
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pathway is utilized by TGF-β1 to stimulate TGF-β2 and TGF-β1 secretion in 
endometrial, endometriotic cell lines and endometrial stromal cells.  
We showed for the first time that TGF-β-induced apoptosis of endometrial and 
endometriotic cells is Smad-dependent and both intrinsic and extrinsic pathways are 
involved. In addition, we showed for the first time the TGF-βs and TBRs interaction 
(Signalosome analysis) in endometrial, endometriotic cells and primary endometrial 
stromal cells. It is tempting to speculate that the observed downregulation of 
receptors on endometriotic cells might suggest an escape mechanism by which 
endometriotic cells tries to evade the growth regulation by TGF-βs. 
Interestingly, we were able to demonstrate ALK-2 as a possible point of cross-talk 
between the BMP and TGF-β pathways besides ALK-3 and ALK-6. However, further 
studies are required to clarify this connection between the two pathways. Finally, for 
the first time, we showed that the endometrial stromal cell line T-HESC demonstrated 
similar characteristics compared to primary endometrial stromal cells. Further 
investigations are needed to analyse the characteristics of other primary cells 
compared to cell lines as these will show a clear picture of what might happen in vivo. 
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5 Summary 
 
Endometriosis is characterized by the presence of endometrial-like cells outside the 
uterus mostly in the ovary and peritoneum. TGF-βs are expressed significantly higher 
in the serum and peritoneal fluid of patients with endometriosis. TGF-βs have been 
also observed in endometriotic sites. Thus, TGF-βs might be involved in the 
pathogenesis of endometriosis. The aim of this study was to investigate the signaling 
pathways of the TGF-βs and possible cross-talks with other pathways. Also, we 
investigated the interaction of the TGF-βs to their receptors.  
In this study, we used four different cell lines including endometrial epithelial and 
stromal cell lines, endometriotic epithelial and stromal cell lines and primary 
endometrial stromal cells. Also, endometrial and ovarian tissues were used.  Our 
results showed that in all  four cell lines  and primary cells studied: (1) TGF-β1 or 
TGF-β2 decreased cell numbers in all cells and the reduction was higher in 
endometrial cells compared to endometriotic cells, (2) TGF-β1 or TGF-β2 induced 
apoptosis in all cells with no significant differences between endometrial or 
endometriotic cells, (3) TGF-β1 or TGF-β2 induced Smad3 phosphorylation in all 
cells studied with higher phosphorylation levels observed in endometrial cells 
compared to endometriotic cells, (4) a TβRI inhibitor completely blocked the TGF-β-
induced reduction in cell numbers, apoptosis, PAI-1 secretion and Smad3 
phosphorylation. A Smad3 inhibitor only partly blocked it. (5) TGF-β1 or TGF-β2 
increased TBRII and TBRIII or TBRI and TBRII interaction with a stronger interaction 
observed in endometrial cells compared to endometriotic cells. (6) A BMP as well as 
an ALK-2 inhibitor completely blocked the TGF-β-induced PAI-1 secretion. In 
contrast, ALK-3 and ALK-6 inhibitors only partly blocked it. (7) A JNK inhibitor 
blocked increased secretion of TGF-β2 and TGF-β1 in TGF-β1-treated cells. (8) Both 
endometrial glands and ovarian endometriotic foci express CK 18 and MUC1 
proteins. 
From these results, we suppose that the reduced responsiveness upon TGF-β 
treatment observed in endometriotic cells compared to endometrial cells in regard to 
reduction in cell numbers, Smad3 phosphorylation and TBR receptor interaction 
indicates that endometriotic cells are more resistant to TGF-β signals. This suggests  
that endometriotic cells might acquire tumor-like characteristics which might 
contribute to their survival, evasion of the immune system and subsequent 
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implantation during the pathogenesis of endometriosis. In addition, we provided 
evidence that endometriotic cells have possibly the same origin from endometrial 
cells and thus are disseminated like tumor cells. Furthermore, we demonstrated for 
the first time that endometrial and endometriotic cells undergo apoptosis upon TGF-β 
treatment and both intrinsic and extrinsic pathways are involved. In addition, we 
demonstrated the participation of the JNK and BMP pathways in TGF-β signaling in 
endometrial, endometriotic and primary endometrial stromal cells. These findings 
might provide new insights into the roles of TGF-βs in the pathophysiology of 
endometriosis. However, more studies are needed on BMP and JNK pathways in 
TGF-β signaling in endometrial, endometriotic and primary cells to elucidate the 
connection between BMP or JNK with TGF-βs since our study only gave a first 
glimpse into involvement in TGF-β signaling in endometrial, endometriotic and 
primary endometrial stromal cells. 
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6. Zusammenfassung 
 
Endometriose ist charakterisiert durch die Anwesenheit von endometrium-ähnlichen 
Zellen ausserhalb des Uterus meistens im Ovar und im Peritoneum. TGF-βs sind 
signifikant stärker exprimiert im Serum und Peritonealflüssigkeit von Patienten mit 
Endometriose. TGF-βs wurden auch beobachtet an endometriotischen Stellen und 
könnten deshalb in der Pathogenese der Endometriose involviert sein. Das Ziel der 
Studie war die Untersuchung der Signalwege der TGF-βs und mögliche  
Wechselwirkungen mit anderen Signalwegen. Ebenso analysierten wir die Interaktion 
der TGF-βs mit ihren Rezeptoren.  
In dieser Studie nutzten wir vier verschiedene Zelllinien eingeschlossen endometriale 
epitheliale und stromale Zelllinien, endometriotische epitheliale and stromale 
Zelllinien und primäre endometriale stromale Zellen. Ebenso wurden endometriale 
und ovarielle Gewebe verwendet. Unsere Resultate zeigten in allen untersuchten vier 
Zelllinien und den primären Zellen: (1) TGF-β1 oder TGF-β2 verminderten die 
Zellzahlen in allen Zelllinien und die Reduktion war höher in den endometrialen 
Zelllinien verglichen mit den endometriotischen Zelllinien, (2) TGF-β1 oder TGF-β2 
induzierten die Apoptose in allen Zelllinien mit keinem signifikanten Unterschied 
zwischen endometrialen oder endometriotischen Zellen, (3) TGF-β1 oder TGF-β2 
induzierten die Phosphorylierung von Smad3 in allen untersuchten Zellen mit 
höheren Phoshorylierungsspiegeln in endometrialen Zellen verglichen zu 
endometriotischen Zellen, (4) ein TβRI Inhibitor blockierte komplett die TGF-β-
induzierte Reduktion der Zellzahlen, der Apoptose, der PAI-1 Sekretion und der 
Smad3 Phosphorylierung. Ein Smad3 Inhibitor dagegen blockierte nur teilweise. (5) 
TGF-β1 oder TGF-β2 erhöhten die Interaktion von TBRII mit TBRIII oder von TBRI 
mit TBRII mit einer stärkeren Interaktion in den endometrialen Zellen verglichen mit 
den endometriotischen Zellen. (6) Ein BMP als auch ein ALK-2 Inhibitor inhibierte 
vollständig die TGF-β-induzierte PAI-1 Sekretion. Im Gegensatz dazu blockierten ein 
ALK-3 oder ein ALK-6 Inhibitor nur teilweise. (7) Ein JNK Inhibitor blockierte die 
erhöhte Sekretion von TGF-β2 und TGF-β1 in TGF-β1-behandelten Zellen. (8) 
Sowohl endometriale Drüsen als auch ovarielle endometriotische Foci exprimieren 
die Proteine CK 18 und MUC1. 
Ausgehend von diesen Resultaten vermuten wir, dass die reduzierte Responsivität 
nach TGF-β Stimulation beobachtet in endometriotischen Zellen im Vergleich zu 
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endometrialen Zellen bezüglich Reduktion der Zellzahlen, der Smad3 
Phosphorylierung und TBR Rezeptor Interaktion darauf hinweist, dass 
endometriotische Zellen resistenter gegenüber TGF-β Signalen sind. Das deutet 
daraufhin, dass endometriotische Zellen möglicherweise Tumor-ähnliche 
Eigenschaften erwerben, die beitragen zu ihrem Überleben, Umgehen des 
Immunsystems und der nachfolgenden Implantation während der Pathogenese der 
Endometriose. Zusätzlich zeigten wir, dass endometriotische Zellen möglicherweise 
alle von endometrialen Zellen abstammen und sich deshalb wie Tumorzellen 
ausbreiten. Des weiteren zeigten wir erstmalig, dass endometriale und 
endometriotische Zellen die Apoptose einleiten nach Stimulation mit TGF-βs und 
daran sowohl der intrinsische als auch der extrinsische Weg beteiligt sind. Ebenso 
konnten wir zeigen, dass es eine Beteiligung des JNK und BMP Signalwegs beim 
TGF-β Signalweg gibt in endometrialen, endometriotischen und primären 
endometrialen stromalen Zellen. Diese Befunde erlauben möglichwerweise neue 
Einblicke in die Rolle der TGF-βs in der Pathophysiologie der Endometriose. 
Dennoch sind mehr Studien zu den BMP und JNK Signalwegen in endometrialen, 
endometriotischen und primären Zellen nötig um die Zusammenhänge zwischen 
BMP oder JNK mit den TGF-βs aufzuklären, weil unsere Studie nur einen ersten 
Eindruck in die Beteiligung der TGF-β Signalwege in endometrialen, 
endometriotischen und primären endometrialen stromalen Zellen vermitteln konnte. 
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